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ABSTRACT OF DISSERTATION 
 
 
 
 
THE EFFECT OF PPARγ ACTIVATION BY PIOGLITAZONE ON THE 
LIPOPOLYSACCHARIDE-INDUCED PGE2 AND NITRIC OXIDE PRODUCTION: 
POTENTIAL UNDERLYING ALTERATION OF SIGNALING TRANSDUCTION 
 
Microglia-mediated neuroinflammation plays an important role in the 
pathogenesis of Parkinson's disease (PD).  Uncontrolled microglia activation produces 
major proinflammatory factors including cyclooxygenase 2 (COX-2) and inducible nitric 
oxide synthase (iNOS) that may cause dopaminergic neurodegeneration.  Peroxisome 
proliferator-activated receptor γ (PPARγ) agonist pioglitazone has potent anti-
inflammatory property.  We hypothesize pioglitazone protects dopaminergic neuron from 
lipopolysaccharide (LPS)-induced neurotoxicity by interacting with relevant signal 
pathways, inhibiting microglial activation and decreasing inflammatory mediators.   
 
First, the neuroprotection of pioglitazone was explored.  Second, the signaling 
transductions such as jun N-terminal kinase (JNK) and the interference with these 
pathways by pioglitazone were investigated.  Third, the effect of pioglitazone on these 
pathways-mediated PGE2 / nitric oxide (NO) generation was investigated.  Finally, the 
effect of PPARγ antagonist on the inhibition of PGE2 / NO by pioglitazone was explored.  
The results show that LPS neurotoxicity is microglia-dependent, and pioglitazone 
protects neurons against LPS insult possibly by suppressing LPS-induced microglia 
activation and proliferation.  Second, pioglitazone protects neurons from COX-2 / PGE2 
mediated neuronal loss by interfering with the NF-κB and JNK, in PPARγ-independent 
mechanisms.  Third, pioglitazone significantly inhibits LPS-induced iNOS / NO 
production, and inhibition of LPS-induced iNOS protects neuron.  Fourth, inhibition p38 
MAPK reduces LPS-induced NO generation but no effect is found upon JNK inhibition, 
and pioglitazone inhibits p38 MAPK phosphorylation induced by LPS.  In addition, 
pioglitazone increases PPARγ phosphorylation, followed by the increased PI3K/Akt 
phosphorylation.  Nevertheless, inhibition of PI3K increases LPS-induced p38 MAPK 
phosphorylation.  Inhibition of PI3K eliminates the inhibitive effect of pioglitazone on 
the LPS-induced NO production, suggesting that the inhibitive effect of pioglitazone on 
the LPS-induced iNOS and NO might be PI3K-dependent. 
 
In summary, the results suggested that pioglitazone protects neurons by inhibiting 
microglia-mediated COX-2 and iNOS, by differentially interacting with LPS-induced 
JNK, NF-kB, and p38 MAPK signaling.  Particularly, pioglitazone reduces JNK-
mediated COX-2 / PGE2 and p38 MAPK-mediated iNOS / NO.  It is worth noting that 
the inhibitive effect of pioglitazone on LPS-induced NO might be dependent on the PI3K 
activation.  In addition, our results suggest that both PPARγ-dependent and PPARγ-
independent mechanisms might be involved in the inhibitive effect of pioglitazone on 
LPS-induced PGE2 and NO generation. 
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CHAPTER 1: Introduction 
 
Idiopathic Parkinson’s disease (IPD) is a common neurological progressive movement 
disorder with an incidence of 1-3% among the population (Bennett et al., 1996; Lang and 
Lozano, 1998).  The primary pathology is the significant loss of pigmented dopaminergic 
neurons in the substantia nigra (SN) and accordingly gradual depletion of striatal 
dopamine, leading to its cardinal movement symptoms: resting tremor, rigidity, slowed 
movement (named bradykinesia), and postural instability.  As of now, pharmacological 
treatment of PD such as levodopa and dopamine agonists can only suppress symptoms.  
Long-term treatment will develop the medication-induced complications such as 
dyskinesias characterized by involuntary and excessive movement.  So it is very 
important to understand the molecular mechanisms underlying its pathogenesis.  Several 
neurotoxins, including 6-hydroxydopamine (6-OHDA) (Ungerstedt, 1968), 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Langston et al., 1984), LPS (Castano et al., 
1998), and rotenone (Betarbet et al., 2000) have been used to study its pathological 
process.   
Although its etiology is still not completely known, chronic neuroinflammation, 
oxidative stress, apoptosis, stress, mitochondrial and proteasomal dysfunction are 
implicated in its pathogenesis (McGeer et al., 1988b; McGeer et al., 1988a; Hirsch et al., 
1997; Jenner, 1998; Greenamyre et al., 1999; Olanow and Tatton, 1999).  Indeed, up-
regulated inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) are 
observed in the postmortem PD brain samples (Knott et al., 2000; Teismann et al., 2003b; 
Teismann et al., 2003a), and are associated with the death of dopaminergic neurons in 
vitro (Okuno et al., 2005; Lin et al., 2007) and in vivo (Liberatore et al., 1999; Teismann 
and Ferger, 2001; Arimoto and Bing, 2003; Vijitruth et al., 2006).   
Peroxisome proliferator-activated receptor γ (PPARγ) activation has been known 
to negatively mediate microglial and macrophage activation (Jiang et al., 1998; Ricote et 
al., 1998; Bernardo and Minghetti, 2006; Drew et al., 2006), which may play a central 
role in the dopaminergic neuronal death.  Recently, there have been a few studies 
demonstrating that activation of PPARγ with its agonists protects dopaminergic neurons 
against MPTP and LPS insult (Breidert et al., 2002; Dehmer et al., 2004; Hunter et al., 
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2007), however, the underlying mechanisms of neuroprotection with PPARγ agonists is 
not completely known.  This part of the dissertation will seek to examine the effect of 
PPARγ activation with its synthetic ligand pioglitazone on the LPS-induced up-regulation 
of COX-2 and iNOS, to explore the potentially differential role of its activation in 
dopaminergic neurons and microglial cells, and to investigate the role of signaling 
transduction pathways (p38 MAPK, JNK, and PI3K/Akt) involved in the LPS-induced 
PGE2 / nitric oxide and their interference with PPARγ agonist.  The first specific aim was 
to investigate whether LPS-induced dopaminergic neuronal loss is microglia-dependent 
or not by utilizing various primary rat cell culture systems.  The second aim focused on 
the role of PPARγ activation in the signaling pathways associated with the LPS-induced 
PGE2 and NO production.  This chapter summarizes the relevant studies on the LPS and 
PPARγ, its interference with cytotoxic molecules including cytokines and 
proinflammatory factors, and its potential to be used in the neurodegenerative diseases.    
Introduction to LPS studies relevant to Parkinson’s disease 
LPS is a strong inducer of neuroinflammation and oxidative stress.  It showed that 
intranigral LPS injection in rats (2μg, from E. coli) induces a decrease in tyrosine 
hydroxylase (TH) positive immunoreactivity with a decrease in the dopamine level on the 
sites of both SN and striatum, which are accompanied with microglia activation (Castano 
et al., 1998).  A further study from same group demonstrated that the neurotoxicity of 
intranigral LPS injection is specific to dopaminergic neurons, compared with 
serotoninergic and GABAergic neurons (Herrera et al., 2000).  All above studies 
implicated an important role of microglia activation in the dopaminergic neuronal death.  
An LPS in vitro rat model showed that LPS (4μg/ml) did not induce dopaminergic 
neuronal loss in a primary mesencephalic culture.  The presence of added microglia, 
however, was associated with the significant loss of dopaminergic neurons.  In addition, 
their study suggested that nitric oxide may mediate microglia-induced dopaminergic 
neuronal death  (Le et al., 2001), consistent with the results from intranigral LPS 
injection study in which the role of microglial iNOS was implicated (Arimoto and Bing, 
2003).  On the other hand, an LPS infusion PD model provided evidence that activated 
microglia-induced superoxide may play a critical role in dopaminergic degeneration (Gao 
et al., 2002).  A few in vitro studies linked the activated MAPKs cascades with the death 
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of dopaminergic neurons (Lund et al., 2005; McLaughlin et al., 2006).  In their study, 
pretreatment of CEP1347, an inhibitor for mitogen-activated protein kinase kinase kinase 
(MAPKKK), suppressed LPS-induced phosphorylation of p38 MAPK and JNK which 
are downstream to MAPKKK, suggesting the involvement of MAPKs during the 
inflammatory response in the microglia.  Very recently, results from an LPS intranigral 
model showed that co-injection of LPS with p38 MAPK inhibitor rescued dopaminergic 
neurons in the SN, accompanied with reduced iNOS expression (Ruano et al., 2006).  
Two years ago, people observed that rat intranigral LPS injection induces COX-2 
expression and PGE2 synthesis in the SN (de Meira Santos Lima et al., 2006), consistent 
with previous results from other studies of PD animal models (Feng et al., 2002; 
Teismann et al., 2003b; Sanchez-Pernaute et al., 2004; Vijitruth et al., 2006).  Almost at 
the same time, a coculture study on mice primary microglia and rat primary neurons upon 
LPS insult suggested that the LPS-induced PGE2 level is increased in a microglia density-
dependent manner (McLaughlin et al., 2006).  The above studies strongly suggested that 
uncontrolled activated microglia-mediated inflammation can be detrimental to 
dopaminergic neurons, probably via the activation of MAPKs pathways and increasing 
iNOS / COX-2 expression.  However, the direct relationship between activated 
microglia-mediated neuroinflammation and the dopaminergic neuronal degeneration is 
still not completely investigated.  Both LPS in vivo and in vitro studies can not rule out 
the neuroprotective and / or neurotoxic role of astrocytic cells under certain conditions 
since either primary mesencephalic cultures or primary mesencephalic-glia cultures were 
used in their studies.  In addition, the biochemical responses of neuronal and microglia 
cell lines to neurotoxin LPS can not be easily compared with the responses from the 
primary cells.  The following Table 1.1 summarizes LPS in vitro and in vivo studies 
relevant to Parkinson’s disease. 
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Table 1. 1 Summary of LPS in vivo and in vitro studies relevant to Parkinson's disease. 
(page 4-5) 
 
Model Doses  Relevant findings Reference  
Intranigral injection 
Wistar rats 
2μg Decreased TH+ cells 
Decreased DA level 
Microglia activation 
(Castano et al., 1998)
Intranigral injection 
Wistar rats 
2μg LPS neurotoxicity is specific to DA neurons 
Microglia activation 
(Herrera et al., 2000)
Coculture of 
primary 
mesencephalic and  
primary microglia 
(rats) 
4 μg/ml TH+ cell loss when microglia added. 
  
(Le et al., 2001) 
Intranigral injection 
SD rats 
5μg iNOS protein increased in SN. 
iNOS inhibitor L-NNA injection in SN 
rescued neurons 
(Arimoto and Bing, 
2003) 
Infusion LPS Fisher 
rats 
5ng/hr x 2 
weeks 
Microglia activation preceded selective 
neuronal loss. 
Superoxide might be important 
(Gao et al., 2002) 
LPS in vitro E15 rat  10-80μg/ml Selective neuronal loss 
iNOS inhibitor L-NIL did not rescue neurons. 
(Gayle et al., 2002) 
Single 
Intraperitoneal 
injection SD female 
rats E10.5, pups 
killed at p21 
1mg/kg Decreased DA neurons 
Decreased DA level 
 
(Ling et al., 2002) 
Intranigral injection 
into NADPH 
deficient mice 
5μg NADPH oxidase-generated ROS mediates 
neurotoxicity 
(Qin et al., 2004) 
Microglia cell line 
(BV-2)   
100ng/ml MAPKs pathway might be involved (Lund et al., 2005) 
Primary 
mesencephalic 
culture; microglia 
culture, PC12 cell 
culture  
1-100ng/ml Caspase-3 activation in dopaminergic 
neuronal loss 
(Wang et al., 2005) 
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Mouse macrophage 
cell line RAW 
264.7,  
dopaminergic cell 
line SH-SY5Y  
10ng/ml NO-dependent neurotoxicity (Shavali et al., 2006) 
Intranigral injection  
 
 
 
1 μg Inhibition of p38 MAPK decreased LPS-
induced iNOS 
(Ruano et al., 2006) 
Intraperitoneal 
injection TNFR1/R2 
deficient mice 
 
5mg/kg  Microglia activation and deceased TH+ cells. 
  
TNFR1/R2-/- resistant to the increase of TNFα 
in brain 
 
(Qin et al., 2007) 
Intrastriatal injection 
SD rats  
 
 
16-60 μg LPS
20mg/kg; 
orally 
administrated 
pioglitazone 
Pioglitazone rescued TH+ neurons with 
inhibition of iNOS and COX-2. 
Pioglitazone suppressed protein oxidation  
(Hunter et al., 2007) 
Table 1.1 continued 
* DA = dopamine; L-NNA= NG-nitro-L-Arginine; L-NG-Nitroarginine, NOS inhibitor; i.c.v = 
intracerebroventricular; TNFR1/R2 = Tumor necrosis factor α receptor 1 / 2; L-NIL = dihydrochloride, 
relative selective inhibitor of iNOS 
General introduction to PPARs  
PPARs are ligand-inducible transcription factors belonging to the superfamily of nuclear 
receptors.  There are three isotypes identified as of now.  They are structurally 
homologous: PPARα (NR1C1) (Issemann and Green, 1990), PPARβ (NR1C2), and 
PPARγ (NR1C3) (Michalik and Wahli, 1999; Torra et al., 2001).  PPARs play a central 
role in the regulation of lipid metabolism and glucose homeostasis, well-known effects 
that have been used to develop drugs for treatment of type II diabetes (Auwerx, 1999).   
Their differential physiological functions are related to their distinct expression 
and localization in a variety of cell types and tissues.  Although they are mainly 
expressed in the tissues with high fatty acid metabolism including liver and adipose tissue, 
the expression of all three isotypes are observed in neurons.  Recently, there has been 
much interest in the potent inhibitive effects of PPARs on inflammation and oxidative 
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stress, suggesting their role in treating neurodegenerative diseases (Heneka et al., 1999; 
Combs et al., 2000; Heneka et al., 2000; Sastre et al., 2003; Bernardo et al., 2005; Heneka 
et al., 2005).     
Distribution of PPARγ and other isotypes 
Developmentally, PPARγ transcription was observed on gestation of day 13.5 in the CNS 
and on 18.5 in the brown adipose tissue in rat and mouse (Heneka and Landreth, 2007).  
High levels of PPARα expression are found in the liver, kidney, intestine, skeletal muscle, 
and the pancreas.  In contrast, PPARβ is expressed ubiquitously and earlier during fetal 
development (more detail in Heneka review (Heneka and Landreth, 2007) ).  In adult 
rodent including rat and mice, the distribution of PPARγ and PPARα is similar to their 
expression observed in the fetal period, and PPARβ transcript is more abundant than the 
PPARα and γ transcripts. 
However, the expression of PPARs is less understood during human development.  
A few studies have showed that human PPARγ is also abundantly expressed in adipose 
tissue, with lower levels in skeletal muscle, the heart, and the liver.  Noticeably, it is 
present in the macrophages (Huang et al., 1999; Barish et al., 2005).  PPARα is most 
highly expressed in tissues with fatty acid catabolism like PPARγ.  Similar to the 
expression pattern observed in the rodent, PPARβ expression is ubiquitous.     
Importantly, expression of all three PPARs is observed in the CNS during late rat 
embryogenesis and in the adult, of which the PPARγ is found dominantly in microglia.  
In astrocytes all three PPAR isotypes are found with different degrees. The following 
table 1.2 summarizes PPAR distribution in the peripheral tissues and in the CNS.
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Table 1. 2 Distribution and functions of PPARs in mammal tissues. 
 
Isotype  Brown 
adipose 
tissue 
White 
adipose 
tissue 
Kidney  Intestine  Heart  Muscle Liver  Pancreas  Rat CNS 
(all 
isotypes 
express in 
brain 
except 
following 
areas or 
cells) 
Functions  
PPARα +++ + ++  ++  ++ ++  +++  ++  Hypothala
mus (-) 
VTA (-) 
Purkinje 
cell (-) 
Granule 
cell (-) 
Oligodend
rocyte (-) 
Lipid 
Catabolism; 
Anti-
inflammation
PPARβ ++ ++ ++ ++ ++ +++ ++ No study  Lipid 
homeostasis;
Oligodendro
cyte  
differentiatio
n? 
Anti-
inflammation
PPARγ 
 
 
 
++ +++ ++ ++ ++  ++  ++  No study VTA (-) 
Purkinje 
cell (-) 
Telenceph
alon (-) 
Oligodend
rocyte (-) 
Lipogenesis; 
Anti-
inflammation 
 
 
VTA = ventral tegmental area; (-) means not found. Empty cell means no study was 
found. 
Based on: (Moreno et al., 2004)
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PPAR structure and putative mechanisms of their function 
Although PPAR isotypes are encoded by distinct genes on different chromosomes, they 
are homologous in structure.  Generally, there are four major domains in the PPAR 
structure.  Their N-terminal A/B domain takes part in the ligand-independent regulation 
of receptor activity, the DNA-binding domain (DBD) is highly conserved among the 
three isoforms and is linked to the C-terminal ligand-binding domain (LBD).  Its E/F 
domain is responsible for the ligand-dependent transactivation function, and its D domain 
is characteristic of a variable hinge region (Kersten, 2000, 89:141).  (Figure 1.1) 
 
 
 
 
Figure 1. 1 PPARs structure  
Four main distinct regions are contained in PPARs, from A/B to E/F domain.  The N-
terminal A/B domain contains ligand-independent activity, C domain contains a DNA-
binding domain, D is characteristic of a variable hinge region, and E/F is ligand-binding 
domain with a ligand-dependent activity. Shown here is its heterodimer retinoic acid 
receptor (RXRα) binding to the peroxisome proliferator response element on the target 
genes.  Modified from (Boitier et al., 2003). 
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Although the exact mechanisms of how PPARs regulate gene expression remains 
elusive, an increasing body of evidence suggested that multiple mechanisms might be 
involved in these processes.   
The first putative mechanism of its transcriptional control of gene expression is 
named ligand-dependent transactivation via heterodimerizing with retinoid-S-receptors 
(RXRs).  As shown in Figure 1.2 (1), coactivators such as CREB-binding protein 
(CBP)/p300 are recruited, and the PPAR-RXR heterodimers binding to the typical PPAR 
response elements (PPREs) on the promoter of target genes then activate related 
transcription (Desvergne and Wahli, 1999; McKenna and O'Malley, 2002).   
Noticeably, PPARs can inhibit proinflammatory gene expression by a second 
putative mechanism named ligand-dependent transrepression via antagonizing the 
activities of other transcription factors, including NF-kB and activator protein-1 (AP-1) 
(Marx et al., 1998; Staels et al., 1998), without involving in PPREs binding, as shown in 
Figure 1.2 (2).  In this way, their target genes transcription can be transrepressed.  A line 
of evidence suggested that anti-inflammation of PPARγ agonists is related to this 
mechanism (Pascual et al., 2005; Glass and Ogawa, 2006).   
The third putative mechanism is named ligand-independent repression via 
interaction of recruited corepressor complexes and PPARs, thus inactivating target genes, 
as shown in Figure 1.2 (3).  Dr. Dowell reported that PPARα can interact with nuclear 
receptor corepressor directly in human embryonic 293 cells (Dowell et al., 1999).  
However, whether other PPAR isotypes can function in this way remains to be studied.  
For more detail see (Ricote and Glass, 2007).   
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Figure 1. 2 Schematic graph shows gene expression by PPARs. 
(1) Ligand-dependent transactivation.  Ligand-binding recruits coactivator complexes, 
bind to PPRE, and activates gene expression.  (2) Ligand-dependent transrepression.  
Ligand-binding with PPAR antagonizes activity of other transcription factor, shown here 
is NF-kB inhibition.  (3) Ligand-independent repression.  Binding of PPAR to RXR 
recruits corepressor complexes, which suppress gene expression.  Modified from (Ricote 
and Glass, 2007). 
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PPARs and neurodegenerative diseases 
Although neurodegenerative diseases are characterized by their distinct pathological 
localization involved in the different groups of cells, excessive reactive microglia are 
frequently observed in patients with Alzheimer’s disease (AD) (Rogers et al., 1988), PD 
(McGeer et al., 1988b), multiple sclerosis (MS)(Gobin et al., 2001), and amyotrophic 
lateral sclerosis (ALS) (Kawamata et al., 1992).  An increasing body of evidence from 
postmortem studies implicates the role of microglia activation-mediated 
neuroinflammation in the pathogenesis of neurodegenerative diseases.  For example, 
elevated levels of proinflammatory factors such as TNF-α and cytokines PGE2 in PD 
(Mogi et al., 1994b; Mogi et al., 1994a; Mogi et al., 1996; Mogi et al., 2007) and AD 
(Griffin et al., 1995) were found near the degenerating neurons.  Animal in vivo and in 
vitro studies of various neurodegenerative diseases showed that inhibition of these 
cytotoxic molecules provides neuroprotection (Misko et al., 1995; Leonard et al., 1997; 
Drachman and Rothstein, 2000; Zhu et al., 2002; Pompl et al., 2003; Nathan et al., 2005; 
Ni et al., 2007; Kotilinek et al., 2008). 
The anti-inflammation activities of PPARs were first noticed when a prolonged 
inflammatory response was observed in PPARα null mice (Devchand et al., 1996). As of 
now, it has been shown that all three PPAR isoforms can participate in the mediation of 
inflammatory response.  PPARβ deficient mice showed delayed would healing and its 
agonist inhibited cytokine-induced vascular cell adhesion molecule in epithelial cells 
(Michalik et al., 2001; Rival et al., 2002).  PPARγ agonist 15-deoxy-D-prostaglandin J2 
(15d-PGJ2) suppresses interferon-γ-induced iNOS protein and its mRNA in mouse 
peritoneal macrophages (Ricote et al., 1998).  Further study demonstrated that its agonists 
can also inhibit proinflammatory factors such as TNF-α and interleukin-6 in different cell 
types (Delerive et al., 2001). 
  Recent evidence indicates that PPAR agonists provide neuroprotection by 
mediating inflammatory processes in animal models of PD (Dehmer et al., 2004),  AD 
(Combs et al., 2000; Landreth and Heneka, 2001), MS (Feinstein et al., 2002), and ALS 
(Kiaei et al., 2005).  
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PPARγ and Parkinson’s disease 
Although the etiology of Parkinson’s disease is still not known, it is generally accepted 
that unlimited activated microglia mediates dopaminergic neuronal loss via releasing 
cytotoxic molecules including cytokines and proinflammatory factors.  It was shown that 
PPARγ activation with 15d-PGJ2 inhibits the level of TNF-α and iNOS protein / mRNA 
expression in mouse peritoneal macrophage (Jiang et al., 1998; Ricote et al., 1998),  
suggesting the effects of PPARγ activation on preventing inflammatory responses in the 
brain.  Indeed, one PPARγ synthetic agonist, troglitazone, suppresses cerebellar iNOS 
expression and protected cerebellar granule cells against LPS/IFN-γ insult (Heneka et al., 
2000).  A few studies from PD animal models have demonstrated that a PPARγ synthetic 
agonist protects dopaminergic neurons accompanying with inhibited microglia activation 
in a mice MPTP model (Breidert et al., 2002; Dehmer et al., 2004).  Three days of orally 
administrated pioglitazone prior to MPTP (i.p) treatment significantly protected 
dopaminergic neurons from death, and iNOS-positive microglial cells were suppressed in 
the pioglitazone-treated group (Breidert et al., 2002); further study from the same 
research group suggested that pioglitazone protected TH positive neurons against MPTP 
insult (30mg/kg i.p.) probably via PPARγ activation, NF-kB activation, and suppression 
of iNOS expression (Dehmer et al., 2004).  Very recently, study on the molecular 
mechanisms of our intrastriatal LPS-induced dopaminergic neuronal loss rat model 
suggested that the dopaminergic neuronal protection by pioglitazone is associated with its 
inhibition of microglia activation, iNOS and COX-2 expression, and restoration of 
mitochondria function (Hunter et al., 2007).  Table 1.3 summarizes current studies of 
PPARγ agonists relevant to PD.  However, 1) the potential inhibitory effect of the PPARγ 
agonist pioglitazone on LPS-induced microglia activation, and 2) the role and signaling 
transduction pathways of pioglitazone in activated microglia-mediated dopaminergic 
neuronal death have not been investigated.  The hypothesis is 1) PPARγ agonist 
pioglitazone inhibits LPS-induced microglia activation; and 2) pioglitazone protects 
dopaminergic neuronal loss against neurotoxicity of microglia-mediated iNOS and COX-
2. 
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Table 1. 3 Summary of current reference relevant to neuroprotection of PPARγ agonists. 
 
 
*ip= Intraperitoneal injection; DA= dopaminergic neurons 
 
 
MAPKs and PI3K in Parkinson’s disease 
From extracellular stimuli such as proinflammatory cytokines to the target gene 
expression, intracellular signaling transduction is tightly regulated in the divergent and 
convergent manner.  One of the best known proinflammatory pathways is mitogen-
activated protein kinases pathways (MAPKs), which include p38 MAPK, JNK, and 
ERK1/2.  Dependent on different extracellular stimuli and different cell types, differential 
Model Major results Reference 
MPTP (i.p) Protect DA neurons 
Inhibition of glial activation 
(Breidert et al., 2002) 
MPTP (i.p) Reduce iNOS positive cells 
Induce IkBα expression 
Inhibit NF-kB nuclear translocation 
(Dehmer et al., 2004) 
Intrastriatal LPS 
injection 
Protect DA neurons 
Inhibition of microglia activation 
Inhibition of iNOS / COX-2 
(Hunter et al., 2007) 
LPS in vitro Protection of DA neurons via inhibiting microglia 
activation 
Inhibition of COX-2 via interference with JNK 
and NF-kB  
(Xing et al., 2007) 
LPS in vitro  Suppresses p38 MAPK activation-mediated iNOS 
possibly via activation of PPARγ and PI3K / Akt 
pathway 
(Xing et al., 2008) 
MPTP (i.p) Protection of DA neurons 
Inhibition of MPTP conversion to MPP+ via 
suppressing MAO-B 
(Quinn et al., 2008) 
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biological responses are tightly controlled following complicated sequential activation 
from MAPKKKs to MAPKs. (Figure 1.3)   
 
 
 
 
Figure 1. 3 Schematic graph of MAPK pathways. 
A variety of extracellular signals such as growth factors and cytokines differentially 
activate MAPKKKs such as Raf, MEKK, MLK, followed by sequential activation of 
MAPKKs such as MEK1/2, and activation of MAPKs (ERK1/2, JNK, and p38), inducing 
different biological responses. Based on (Gallo and Johnson, 2002) and website: 
http://www.bch.msu.edu/faculty/gallo.htm. 
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It is generally accepted that p38 MAPK and JNK pathways are two main 
signaling cascades that modulate inflammatory response and stress (Kyriakis and Avruch, 
2001).  One small postmortem study on PD brains demonstrated the immunoreactivity of 
their phosphorylation (Ferrer et al., 2001), and a very recent analysis from the extracts of 
leukocytes from PD patients provided more evidence that the JNK activity was reduced 
(White et al., 2007), suggesting these pathways are involved in the pathogenesis of PD.  
On the other hand, experimental animal in vivo and in vitro studies strongly 
implicated MAPK activation-mediated dopaminergic neuronal death in a MPTP / MPP+ 
model (Du et al., 2001; Gomez-Santos et al., 2002), 6-OHDA (Choi et al., 2004; Gomez-
Lazaro et al., 2008), rotenone (Zhao et al., 2006) and other models (Gomez-Santos et al., 
2003; Wilms et al., 2003; Choi et al., 2004; de Bernardo et al., 2004; Lee et al., 2005).  
Although the involvement of p38 MAPK cascade with LPS-induced neuronal death in the 
hippocampus was reported (de Bock et al., 1998), the MAPKs signaling transduction 
associated with LPS-induced dopaminergic neuronal loss is still poorly understood. The 
result from an in vitro study suggested that LPS-induced neuronal loss is prevented by the 
inhibition of p38 MAPK pathway, accompanied by the decrease of NO production in the 
primary mesencephalic culture (Jeohn et al., 2002).  The other in vivo experimental study 
demonstrated that inhibition of p38 MAPK not only rescues dopaminergic neurons but 
also decreases iNOS expression (Ruano et al., 2006).  The role of the JNK pathway in the 
LPS model is less studied.  The result from a midbrain slice culture study suggested that 
inhibition of JNK activity rescues LPS/IFNγ-induced dopaminergic neuronal loss without 
influencing iNOS expression (Shibata et al., 2006), suggesting that the activation of LPS-
induced p38 MAPK and JNK pathways potentially mediates differential production of 
cytotoxic molecules which ultimately lead to neuronal death.  Recently, one clinical trial 
(2007) on 806 patients with early PD using CEP1347, an inhibitor of JNK signaling 
cascade, was done by the Parkinson Study Group.  Although the results did not show 
beneficial slowing down of the progression of PD, it suggests that the therapeutic 
strategies should take multiple signaling cascades associated with inflammatory response 
into account. The hypothesis is that LPS-induced activation of MAPK pathways 
differentially mediate the iNOS/NO and COX-2 / PGE2 expression. 
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 PI3K phosphatidylinositol-3-OH kinase (PI3K) / Akt (also known as protein 
kinase B, PKB) is a well-known cell survival signaling pathway.  Neurotrophic factors 
such as nerve growth factor, brain-derived neurotrophic factor, and insulin-like growth 
factor I activate the PI3K/Akt cascade and promote neuronal survival and / or axonal 
growth (Halvorsen et al., 2002; Nusser et al., 2002; Bonnet et al., 2004; Zhou et al., 2004; 
Yoshii and Constantine-Paton, 2007).  Neurotoxin studies in animals provided a link of 
PI3K activity with neuronal survival (King et al., 2001; Halvorsen et al., 2002).  Their 
results demonstrated that inhibition of PI3K by LY294002 promotes MPP+-induced SH-
SY5Y apoptosis, and activation of Akt can protect cells (King et al., 2001), and nerve 
growth factor treatment prevents SH-SY5Y apoptosis possibly via increasing the 
phosphorylation of PI3K / Akt (Halvorsen et al., 2002).  However, the potentially 
differential regulation of MAPK and PI3K pathways by PPARγ activation and their 
differential roles in the LPS-induced iNOS and COX-2 expression is not completely 
understood.  The hypothesis is that the PPARγ agonist pioglitazone protects 
dopaminergic neurons by the inhibition of iNOS and COX-2 expression via potentially 
differential mediation of MAPK and PI3K activity. 
Overview of experimental aims 
Although intensive studies have been done to investigate the molecular mechanisms of 
the pathogenesis in PD, and several common mechanisms such as neuroinflammation and 
oxidative stress are generally accepted, the role of neuroinflammation-mediated signaling 
transduction in dopaminergic neuronal loss and their interference with PPARγ agonist is 
poorly understood.  The experimental studies described in this dissertation primarily 
address the following general hypotheses: 1) LPS-induced dopaminergic neuronal death 
is microglia-dependent.  It is easy to manipulate different primary cell cultures and 
differentiate the role of microglial activation in the degeneration of dopaminergic neurons. 
2) a PPARγ agonist protects against LPS-induced neurotoxicity via inhibiting p38 MAPK 
/ JNK pathways, which potentially have differential roles in mediating iNOS and COX-2 
expression.  3) a PPARγ agonist might also protect dopaminergic neurons via activating 
the PI3K/Akt pathway, which probably mediates p38 MAPK / JNK activity.  The 
detailed hypotheses and specific aims will be presented in each chapter. 
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  The general profile of PPARγ activation by its synthetic ligand pioglitazone and 
the influence of LPS on its activation were evaluated by western blot.  To measure the 
effect of PPARγ activation by pioglitazone on LPS-induced microglial activation and 
dopaminergic neuronal loss, primary microglia-enriched cultures, primary neuron-
microglia mixed culture and primary neuron-enriched cultures were used, and 
immunocytochemistry for microglia and TH positive neurons was done.  The effect of 
PPARγ activation on the activity of MAPKs (p38 MAPK and JNK) and the PI3K/Akt 
pathway was evaluated by western blot, and the selective inhibitors of p38 MAPK 
(SB203580) and JNK (SP600125) were used to access the effect of their inhibition on 
LPS-induced PGE2 and nitric oxide production in primary microglia-enriched cultures.  
The role of PI3/Akt activation in the mediation of p38 MAPK / JNK activity was 
evaluated by its selective inhibitor wortmannin in primary microglia-enriched cultures.  
The effect of PPARγ activation on the activity of the COX-2 and iNOS, which are the 
rate-limiting enzymes for PGE2 and NO, respectively, was measured by western blot.  
The inhibition of COX-2 and iNOS on LPS-induced dopaminergic neuronal loss was 
evaluated by immunocytochemistry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Bin Xing 2008 
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CHAPTER 2: Dopaminergic neuronal loss induced by LPS is microglia-dependent 
and PPARγ activation by pioglitazone is neuroprotective by inhibiting LPS-induced 
microglial activation 
(From published paper: B Xing., M Liu., GY Bing. (2007) J. Neuroimmunol. 192:89-98).  M Liu took part 
in the experiment in the immunocytochemistry. 
Introduction  
It has been demonstrated that glial-related cytokines are increased either in PD 
postmortem study or in the assay of patients’ serum / cerebrospinal fluid (CSF).  The 
level of TNF-α from PD striatum and CSF is significantly higher than that in the control 
group (Mogi et al., 1994a),  and other cytokines including IL-6 and IL-1β are also 
increased in the dopaminergic regions (Mogi et al., 1994b).  
Although both activated glial cells (microglia / astrocytes) can release 
proinflammatory cytokines under certain cellular stress, and may take part in the 
detrimental process resulting to the death of dopaminergic neurons, increasing evidence 
indicates that activated microglia rather than astrocytes play a major role in the 
pathological process of PD.  First, a large number of reactive microglia was found 
surrounding dopaminergic neurons in the SN of PD brains (McGeer et al., 1988b).  
Second, the SN area where dopaminergic neurons are degenerated has the highest density 
of microglia in the brain, whereas astrocytes have a higher density in the hippocampus 
and hypothalamus (Lawson et al., 1990; Savchenko et al., 2000).  Third, a postmortem 
SN study found that glial fibrillary acidic protein (GFAP) immunoreactivity for 
astrocytes is often unobservable compared to the strong microglial immunostaining 
(Banati et al., 1998).  Fourth, animal experimental studies demonstrated that neurotoxin-
induced dopaminergic neuronal death is often preceded by microglia activation (Gao et 
al., 2002). 
As a potent inducer of inflammation, the LPS PD model provides a very useful 
tool to study the mechanisms of microglia-mediated neuroinflammation in the 
pathological process of PD, since LPS selectively induces the death of dopaminergic 
neurons  (Herrera et al., 2000) and microglia activation (Castano et al., 1998).  The LPS 
in vitro model provides a useful chance to study the detrimental role of both astrocytes 
and microglia.  However, the current in vitro model did not mechanically remove the role 
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of astrocytes since either primary mesencephalic cultures or primary mesencephalic-glia 
cultures were used in their studies.  In this way, it is relatively difficult to explain the data.  
To investigate the activated microglia-mediated neuroinflammation and the dopaminergic 
neuronal degeneration, our LPS in vitro model systems were set up.  From the reports 
that LPS neurotoxicity is glia-dependent (Bronstein et al., 1995), the first hypothesis is 
that LPS neurotoxicity is microglia-dependent and pioglitazone protects dopaminergic 
neurons by inhibiting microglia activation.  The first specific aim is to administer LPS 
into both primary neuron-enriched cultures and primary neuron-microglia mixed cultures, 
then to test the survival of dopaminergic neurons, and to obtain the optimal (minimal) 
LPS toxicity concentration for the future study.  
Several studies have suggested that PPARγ agonists inhibit macrophage / 
monocyte activation-derived cytokines such as TNF-α and NO (Jiang et al., 1998; Ricote 
et al., 1998).  MPTP animal studies showed neuroprotection of a PPARγ agonist toward 
dopaminergic neurons (Breidert et al., 2002; Dehmer et al., 2004).  The second 
hypothesis is that the PPARγ agonist pioglitazone protects dopaminergic neurons via 
inhibiting microglia activation in LPS in vitro model.  The second specific aim is to test 1) 
if pioglitazone inhibits LPS-induced microglia activation, and 2) if pretreatment of 
pioglitazone into primary neuron-microglia mixed cultures shows a neuroprotective 
effect. 
Materials and methods 
 Animals 
Twenty one timed-pregnant Sprague Dawley rats obtained from Harlan (Indianapolis, IN, 
USA) and were maintained in a strict pathogen free environment.  Animal use was 
performed in strict accordance with the National Institutes of Heath guidelines and was 
approved by the Institute’s Animal Care and Use Committee at the University of 
Kentucky. 
 Reagents 
Salmonella minnesota LPS and pioglitazone were obtained from Sigma-Aldrich (St Louis, 
MO, USA),  Ara-C was obtained from Sigma-Aldrich (St Louis, MO, USA), antibodies 
used were as follows: polyclonal anti-tyrosine hydroxylase (TH) antibody from Pel-Freez 
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Biologicals (Rogers, AR, USA), monoclonal anti-rat CD11blc antibody for OX-42 from 
Pharmingen (San Jose, CA, USA), and monoclonal anti-β-actin from Sigma-Aldrich (St. 
Louis, MO, USA).  The ABC kit and biotinylated secondary antibodies were purchased 
from Vector Laboratories (Burlingame, CA, USA).  All culture medium and products 
were obtained from Invitrogen (Carlsbad, CA, USA).  
Mesencephalic neuron-microglia mixed cultures 
Neuron-glia cultures were prepared from the SD ventral mesencephalic tissues of 
embryonic day 13-14.  Briefly, midbrain tissues were dissected from day 14 SD rat 
embryos in Ca++/Mg++ free medium (CMF).  Cells were dissociated via gentle 
mechanical trituration in Hanks’ Balanced Salt Solution (HBSS) containing newborn calf 
serum (3.5:1 v/v).  The concentration of the cell suspension was ~ 1.2 x 107 cells / ml 
before seeding, and the cells were seeded in poly D-lysine (50μg/mL) pre-coated 24-well 
plates (1 x 105/well).  Cells were fed with Dulbecco’s Modified Eagle Medium (DMEM / 
F12) containing 10% horse serum and 10% fetal bovine serum.  Three days after seeding, 
the cells were replenished with 500ml of fresh DMEM / F12 with 5% horse serum and 
fetal bovine serum.  At DIV6 or DIV7, 2 x 105 microglia were added into primary 
mesencephalic neuron-enriched cultures containing 1 x 105 cells/well, and after 24h, the 
cultures were treated with either pioglitazone or LPS dissolved in DMSO, and the control 
groups were only treated with same amount of DMSO (10μl). 
Primary mesencephalic neuron-enriched cultures 
Twenty four hours after seeding, 5μM Ara-C was added into the culture medium for 48h, 
followed by replacement with fresh DMEM / F12 medium with 5% horse serum and fetal 
bovine serum.  Cultures were exposed to treatment seven days after seeding. 
Microglia-enriched cultures 
Primary glial cell cultures were established from cerebral cortices of 2-3 day-old neonatal 
SD rats.  Briefly, cerebral cortices were minced and gently dissociated by repeated 
pipetting in HBSS supplemented with fetal bovine serum (3.5:1 v/v).  Cells were 
collected by centrifugation at 1000g for 6mins, resuspended in DMEM containing 10% 
fetal bovine serum, 100U/ml penicillin, and 100μg/ml streptomycin, and were cultured on 
175cm2 cell culture flasks in 5% CO2 at 37°C.  Floating microglia were harvested 
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between 2-8 weeks by shaking off at 200rpm, and the concentration of the cell 
suspension was ~1.4 x 106 microglial cells/ml and were re-seeded back into 24-well 
plates (2 x 105) for other assays.  After 30mins, cultures were washed to remove non-
adherent cells and fresh medium was added, and the cultures were treated 24h after 
seeding. 
Immunocytochemistry 
Culture medium was removed and the cells were rinsed in Tris buffer (pH = 7.3), fixed in 
4% paraformaldehyde for 20mins, and rinsed again in Tris.  Non-specific staining was 
blocked with 10% goat serum or horse serum for 60mins.  Cells were incubated overnight 
at 4°C with primary anti-TH antibody (1:10,000) or anti-OX-42 primary antibody 
(1:1000).  After several Tris rinses, cells were incubated with the following biotin-
conjugated secondary antibodies for 1hr:  goat anti-rabbit IgG (1:1000) for TH or horse 
anti-mouse IgG (1:1000) for OX-42.  The cells were rinsed several times and incubated 
in an ABC-peroxidase reagent for 1hr.  This was followed by several rinses and a color 
development with 3,3'-diaminobenzidine and 0.03% H2O2 in Tris buffer.  Images were 
acquired using a Zeiss Axioplan 2 microscope connected to a digital Zeiss Axio camera 
operated with AxioVision software (Zeiss).  To quantify OX-42 positive cells, nine 
representative areas per well, in the 24-well plate, were counted under the microscope at 
100X magnification, and the microglia with an expanding transparent part were 
considered as activated.  The TH-positive neurons were counted in each 24-well plate, 
and the averages are reported.  TH-immunostained neurons were considered healthy, if 
the length of all the neurites was two times longer than the diameter of its cell body and if 
the cell had at least two neurites.  
Statistical Analysis 
The data are expressed as the mean ± SEM and statistical significance was assessed by 
ANOVA followed by a Tukey comparisons test using the SYSTAT 10 software (SPSS 
Inc., Chicago, Illinois).  A value of p < 0.05 was considered statistically significant.   
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Results  
LPS neurotoxicity is microglia-dependent and the PPARγ agonist pioglitazone protects 
dopaminergic neurons against LPS insult 
It has been shown that LPS neurotoxicity is glia-dependent in mesencephalic cultures 
(Bronstein et al., 1995), but the effect of astrocytes were not excluded in their study.  In 
order to test if LPS toxicity in our culture system is microglia-dependent, and to facilitate 
studying the cellular and molecular mechanisms between initial microglial activation and 
secondary dopaminergic neuronal death, the survival of TH-positive neurons upon LPS 
exposure, in the presence and absence of microglia, was investigated in primary neuron-
enriched and neuron-microglia mixed cultures. We found that LPS failed to induce 
dopaminergic neuronal loss in neuron-enriched cultures (Figure 2.1).  In contrast, in the 
presence of microglia, 1-40μg/ml LPS induced ~38-75% loss of the dopaminergic 
neurons (Figure 2.2) after a 72hr LPS treatment.  Pretreatment with pioglitazone (10μM), 
1hr prior to LPS (1μg/ml), significantly protected dopaminergic neurons by about 90% 
compared to the 60% cell loss upon LPS (1μg/ml) alone (p<0.05, Figure 2.2).  
Pioglitazone alone did not alter cell viability. 
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Figure 2. 1 LPS treatment in primary neuron-enriched cultures. 
Rat mesencephalic neuron-enriched cultures (1×105 cells/well) were treated with LPS for 
72 h, and examined with immunocytochemistry for TH-positive neurons.  A:  Increasing 
concentrations of LPS (a–h) did not decrease the number of TH-positive neurons.  Both 
control and LPS treated groups had long smooth neuritis.  B: No significance difference 
was found between control group and different doses of LPS groups (5ng/ml-40μg/ml).  
The data were expressed as the percentage of control and were the mean ± SEM, from 
three independent experiments. (n=3). (a=control; b=LPS 5 ng/ml; c=LPS 10 ng/ml; 
d=LPS 50 ng/ml; e=LPS 100 ng/ml; f=LPS 1 μg/ml; g=LPS 10 μg/ml; h=LPS 40 μg/ml). 
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Figure 2. 2 LPS is neurotoxicity in neuron-microglia mixed cultures. 
Rat neuron-microglia cultures (with 1×105 neurons and 2×105 microglia per well) were 
treated with various doses of LPS (5ng–40μg/ml) for 72 h, and the number of TH-
positive neurons was examined with immunocytochemistry.  A: control cultures have 
long and smooth neurites (a), LPS (1μg/ml) treated cultures have discontinuous neurites 
(b), and LPS (1μg/ml – 40μg/ml) induces a dose-dependent neurotoxicity as indicated by 
the discontinuous neurites (b). Pioglitazone (10μM) alone did not influence the general 
morphology and survival of the TH positive neurons (c).  Pretreatment with pioglitazone 
(10μM) 1 h before LPS (1μg/ml) treatment represented in (d) showed normal 
morphology.  B: LPS did not show neurotoxicity from 0.005μg/ml to 0.5μg/ml, however, 
1μg/ml-40μg/ml LPS showed dose-dependent neurotoxicity.  C: LPS (1μg/ml) decreased 
the number of TH positive neurons, and pretreatment of pioglitazone protected the TH-
positive neurons against cell death, as determined by cell counts.  The data were 
expressed as the percentage of control and were the mean ± SEM, from three independent 
experiments. (n=3) (**p<0.01 versus control, #p<0.05 versus LPS). 
   
Pioglitazone suppresses LPS-induced microglia activation 
LPS did not induce dopaminergic neuronal loss in the absence of microglia and 
pioglitazone protected dopaminergic neurons against LPS neurotoxicity in the presence 
of microglia, suggesting its neurotoxicity is dependent on microglia.  In the next step we 
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tested the effect of pioglitazone on microglia activation.  First, microglia-enriched 
cultures were treated with LPS (100ng-1μg/ml) in the presence or absence of pioglitazone 
(10μM) for 24 and 48h.  Then, microglia activation was determined by the obvious 
swelling and morphological changes of the OX-42 positive cells.  After 24h of 100ng/ml 
LPS exposure, 45% of the microglia were activated, and 60% microglia activation was 
observed with 1μg/ml LPS (Figure 2.3).  In contrast, pretreatment with pioglitazone, 1hr 
before LPS, suppressed microglia activation to the control level (p<0.01).  After 48h, 
LPS activated ~80% of the microglia (Figure 2.4), and pretreatment with pioglitazone 
(1μM and 10μM) significantly suppressed microglial activation within 50% and 30%, 
respectively.  In addition, the suppressive effect of pioglitazone (10μM) on the LPS-
induced microglia proliferation is observed in primary microglia-enriched cultures after 
48h LPS exposure (Figure 2.5).  
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Figure 2. 3 Pioglitazone inhibits microglia activation in rat microglia-enriched cultures 
(24hr). 
Twenty four hours after seeding (2×105 cells/well) into 24-well plates, cultures were 
treated with LPS (0.1 μg/ml–1 μg/ml) for 24h, and immunostaining for OX-42 was done.  
A: Microglia in control (a) are small than in the LPS-treated group (b) (1 μg/ml), in 
which the cells swelled, as represented by an arrow. The cell morphology did not change 
in the pioglitazone alone group (c), and pretreatment with pioglitazone 10μM had less 
swollen cells (d).  B: The different doses of LPS activated 50%–60% of the microglia, 
and pretreatment with pioglitazone (10μM) significantly attenuated microglia activation. 
The data were expressed as the percentage of control and were the mean ± SEM, from 
three independent experiments. (n=3) (**p<0.01 versus control; ##p<0.01 versus LPS). 
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Figure 2. 4 Pioglitazone inhibits microglia activation in rat microglia-enriched cultures 
(48hr). 
Twenty four hours after seeding (2×105 cells/well) into 24-well plates, cultures were 
treated with LPS (0.1μg/ml–1μg/ml) for 48h, and immunostaining with OX-42 was done. 
A: In LPS-treated group (b), the immunostained cells become much bigger than control 
group (a). An arrow in LPS-treated group indicates a typical activated microglia.  
Pioglitazone alone did not change morphology of the cells (c), and pretreatment with 
pioglitazone reduced the activated microglia (d), with some difference in their shape.  B: 
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Forty-eight hours of LPS exposure activated about 80% of the microglia in LPS group 
(0.1μg/ml and 1μg/ml), and pretreatment with pioglitazone (1μM or 10 μM) significantly 
reduced microglia activation. The data were expressed as the percentage of control and 
were the mean ± SEM, from three independent experiments. (n=3) (**p<0.01 versus 
control; ##p<0.01 versus LPS). 
 
 
 
Figure 2. 5 Pioglitazone inhibits LPS-induced microglia proliferation (48hr). 
Twenty four hours after seeding (2×105 microglia cells/well) into 24-well plates, cultures 
were treated with LPS (1μg/ml) for 48 h, and immunostained with OX-42.  Forty-eight 
hours of LPS exposure increased the number of microglia, however, pretreatment with 
pioglitazone (10μM) reduced microglia proliferation. The data were expressed as the 
percentage of control and were the mean ± SEM, from three independent experiments. 
(n=3) (*p<0.05 versus control; #p<0.05 versus LPS). 
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Discussion  
The results show that LPS neurotoxicity is microglia-dependent, and the PPARγ agonist 
pioglitazone protects dopaminergic neurons against LPS insult via inhibiting microglia 
activation.  The current study shows that our in vitro cell culture system can be used as a 
reasonable tool to further study the molecular mechanisms of neuroinflammation-
mediated dopaminergic neuronal death.  
 The brain has been considered as an immunological privileged site based on the 
fact that blood-brain-barrier protects the brain from immune reaction.  However, 
increasing evidence suggested that this postulation may have exceptions; especially under 
the condition that microglia is excessively activated.  LPS-induced systematic 
inflammation causing parkinsonism was reported from a case study (Niehaus et al., 2004), 
in which a laboratory worker was contaminated with LPS (Salmonella minnesota, 
10μg/ml) by wound in an accident and developed parkinsonism after three weeks 
(Niehaus et al., 2004).  Importantly, microglia activation but not reactive astrocytes has 
been previously demonstrated in the SN of PD brains (McGeer et al., 1988b; Mirza et al., 
2000), and a growing body of evidence suggested that microglia activation could play a 
critical role in mediating the survival of dopaminergic neurons in the PD midbrain (Ouchi 
et al., 2005) as well as in animal models of Parkinson’s disease (Czlonkowska et al., 1996; 
Lu et al., 2000; Le et al., 2001; Gao et al., 2002; Wu et al., 2002; Arai et al., 2004; Wang 
et al., 2006; Hunter et al., 2007; Purisai et al., 2007).   
The present study clearly demonstrates that LPS treatment of neuron-enriched 
cultures fails to induce TH-positive cell loss, however, in the presence of microglia, a 
dose-dependent TH-positive cell loss is observed with LPS treatment.  This suggests that 
the toxic effects of LPS on the mesencephalic dopaminergic neurons are dependent on 
microglia activation and the subsequent release of proinflammatory factors, which is 
consistent with the study from other labs (Liu et al., 2003; Qian et al., 2006; Mount et al., 
2007; Zhao et al., 2007).  While the causal relationship of microglial activation and 
dopaminergic neuron survival is still debatable, our finding that LPS failed to show 
dopaminergic neurotoxicity in the absence of activated microglia supports the idea that 
uncontrolled microglia activation can initiate dopaminergic neurodegeneration.  
Pioglitazone significantly reduced the LPS-induced dopaminergic neuronal loss, 
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suggesting its neuroprotective effect is related to its inhibiting microglia activation, which 
can initiate neuronal loss by increasing proinflammatory factors such as superoxide, NO, 
cytokines, and prostaglandins  (Banati et al., 1993; Minghetti and Levi, 1998).  The 
protective effects of pioglitazone are in line with several previous studies that 
demonstrated significant protection with pioglitazone in the MPTP PD model (Breidert et 
al., 2002; Dehmer et al., 2004), experimental autoimmune encephalomyelitis (EAE) 
model (Storer et al., 2005), transient cerebral ischemia model (Victor et al., 2006), and 
LPS PD model (Hunter et al., 2007).   
 Traditionally, three classic types of microglia in terms of their morphology 
(ameboid, ramified, and intermediate) was described according to observation from silver 
carbonate staining developed 70 years ago (del Rio Hortega, 1932; Kershman, 1939). 
With the gradual understanding of microglial function, the classification of microglia is 
switched according to their activation condition: resting microglia, activated microglia, 
and phagocytic microglia (Streit et al., 1989) .  In our culture system, LPS increases the 
ratio of activated microglia and pioglitazone inhibits their activation.  On the other hand, 
we observed that the total number of microglia, including activated and non-activated 
microglia, is significantly less in the pioglitazone treated group in microglia-enriched 
culture, suggesting pioglitazone suppresses LPS-induced microglia proliferation.  Indeed, 
it showed that the proliferation rate of microglia is increased upon LPS stimuli 
(Shankaran, 2007), and the PPARγ agonist 15d-PGJ2 induces microglial death (Bernardo, 
2003).  However, two basic phenotypes of microglia were observed in the primary glial 
cultures (Floden and Combs, 2007),  and recently subsets of microglia in the mouse brain 
were studied showing two cell groups with distinct ability to produce ROS (Nagatsu and 
Sawada, 2006).  It will be very informative to know the potential differential role of 
PPARγ agonists in the microglia with different phenotypes, thus targeting the microglia 
specifically detrimental to the dopaminergic neurons can be an effective strategy for PD 
treatment.  Another interesting question is: By what mechanisms does pioglitazone 
inhibit microglia proliferation?  PGE2 is known to induce microglia death, probably via 
its receptor EP2 and cAMP signaling, however, the present result showed that the 
decrease in PGE2 level by pioglitazone is parallel with the decrease of microglia 
proliferation.  Whether pioglitazone induces microglia death via modulating the 
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expression of its cell cycle protein is interesting to be explored.  Our result suggested that 
the inhibitory effect of pioglitazone on microglia proliferation is LPS-dependent, since no 
significant difference of microglia proliferation was observed between the control and 
pioglitazone groups.  The result is consistent with several studies, which demonstrated 
that the PPARγ agonist BRL49653 induces significant macrophage apoptosis upon 
cytokine TNF-α/IFNγ stimuli by DNA fragmentation assay (Chinetti et al., 1998) and 
ciglitazone induces the death of activated microglia (Yang et al., 2006).  Based on the 
observation of LPS-dependent inhibition of proliferation in our experimental context, it is 
reasonable to speculate that certain active molecule(s) released from activated microglia 
take part in the PPARγ-mediated stress-dependent regulation on the microglia 
proliferation.      
 In summary, our present results demonstrate that LPS neurotoxicity is microglia-
dependent, and pioglitazone protects dopaminergic neurons via suppressing microglia 
activation and / or microglia proliferation.  In the next chapter (3), the underlying 
mechanisms of LPS-induced dopaminergic neuronal loss and its interference by 
pioglitazone were explored, focusing on the signaling transduction relevant to LPS-
induced COX-2 / PGE2.  
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CHAPTER 3: Neuroprotective effect of PPARγ activation with pioglitazone via 
inhibiting COX-2 activity is associated with its inhibition of NF-kB and JNK 
activation 
(From published paper: B Xing., M Liu., GY Bing. (2007) J. Neuroimmunol. 192:89-98).  M Liu took part 
in the experiment in the immunocytochemistry. 
 
Introduction  
In Chapter 2, microglia-dependent LPS neurotoxicity was demonstrated, and it also 
showed that the PPARγ agonist pioglitazone protects dopaminergic neurons against LPS 
insult in our culture systems.  The questions addressed in this chapter are: 1) the potential 
inhibitive effect of pioglitazone on LPS-induced COX-2 / PGE2, and 2) the potential 
interference of pioglitazone on the related signaling transduction pathways - NF-kB and 
JNK.   
A few postmortem studies demonstrated that the activity of NF-kB and COX-2 
are significantly increased in the SN and striatum of PD brain (Hunot et al., 1997; 
Teismann et al., 2003b).  The percentage of immunoreactive nuclear NF-kB in PD 
midbrain is increased 70 fold compared to control samples (Hunot et al., 1997). The 
microglial-related iNOS immunoreactivity in the PD SN and COX-2 / PGE2 level in 
ventral midbrain are increased 3 fold compared to the control group (Teismann et al., 
2003b).  
It is known that JNK and NF-kB are important mediators of inflammation 
associated with COX-2 activity and its production of PGE2 (Uto et al., 2005; Won et al., 
2005; Nieminen et al., 2006).  One study reported c-Jun activation in  MPTP-induced PD 
and in the dopaminergic neurons of PD patients, where deficiency of JNK prevented 
neurodegeneration accompanied by a decrease in COX-2 expression (Hunot et al., 2004).  
We have showed PPARγ agonism with pioglitazone protects SN dopaminergic 
neurons against intrastriatal LPS insult, which was associated with COX-2 inhibition 
(Hunter et al., 2007).  In addition, pioglitazone protects dopaminergic neurons against 
MPTP insult by inhibition of NF-kB (Breidert et al., 2002; Dehmer et al., 2004).  
However, the effect of pioglitazone on JNK-mediated COX-2 and PGE2 generation upon 
LPS insult has not been studied.  The hypotheses in this chapter are: 1) pioglitazone 
inhibits LPS-induced COX-2 expression and PGE2 synthesis; 2) pioglitazone protects 
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dopaminergic neurons against LPS insult via inhibiting COX2 / PGE2 level by interfering 
with NF-kB and JNK pathway.  The specific aims are: 1) to test inhibitory effect of 
pioglitazone on LPS-induced COX-2 expression by western blot, and PGE2 level by EIA 
assay; 2) to measure the role of COX-2 inhibition in the survival of TH positive neurons 
by using a selective COX-2 inhibitor CAY10404; 3) to test the inhibition of NF-kB / JNK 
by pioglitazone using western blot analysis, and to test the role of NF-kB and JNK 
inhibition in the LPS-induced PGE2 synthesis by using selective inhibitors.   
 
Materials and methods 
Animals 
Twenty one timed-pregnant Sprague Dawley rats were obtained from Harlan 
(Indianapolis, IN, USA) and were maintained in a strict pathogen free environment.  
Animal use was performed in strict accordance with the National Institutes of Heath 
guidelines and was approved by the Institute’s Animal Care and Use Committee at the 
University of Kentucky. 
Reagents 
Salmonella minnesota LPS and pioglitazone were obtained from Sigma-Aldrich (St Louis, 
MO, USA).  Selective inhibitors were as follows: T0070907-PPARγ inhibitor and 
CAY10404–COX-2 inhibitor from Cayman (Ann Arbor, MI, USA), SP600125-JNK 
inhibitor from A.G. Scientific (San Diego, CA, USA), and sulfasalazine-NF-kB inhibitor 
from Sigma-Aldrich (St. Louis, MO, USA).  Antibodies used were as follows: polyclonal 
anti-tyrosine hydroxylase (TH) antibody from Pel-Freez Biologicals (Rogers, AR, USA), 
polyclonal anti-COX-2 and polyclonal anti-NF-kB p65 from Cell Signaling (Danvers, 
MA, USA), monoclonal anti-phospho-JNK antibody Santa Cruz (Santa Cruz, CA, USA), 
and monoclonal anti-β-actin from Sigma-Aldrich (St. Louis, MO, USA).  The other 
reagents and culture medium were the same as those mentioned in chapter 2.  
Mesencephalic neuron-microglia mixed cultures 
The same methods were used as mentioned in chapter 2.  Briefly, midbrain tissues were 
dissected from day 14 SD rat embryos, dissociated via gentle mechanical trituration, and 
the cells were seeded in poly D-lysine (50μg/mL) pre-coated 24-well plates (1x105/well) 
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or in pre-coated 6-well plates for western blot (1x106 or 2x106 cells/well).  Cells were fed 
with DMEM/F12 containing 10% horse serum and 10% fetal bovine serum.  Three days 
after seeding, the cells were replenished with fresh medium.  At DIV6 or DIV7, 
microglia were added into primary mesencephalic neuron-enriched cultures containing 
1x105 cells/well, and after 24h, the cultures were treated with either pioglitazone or LPS 
dissolved in DMSO, and the control groups were only treated with same amount of 
DMSO (10μl).   
Primary mesencephalic neuron-enriched cultures 
Cultures were exposed to treatment seven days after seeding. 
Microglia-enriched cultures 
Primary glial cell cultures were established from cerebral cortices of 2-3 day-old neonatal 
SD rats.  Briefly, cerebral cortices were minced and gently dissociated.  Cells were 
collected by centrifugation and were cultured in 175cm2 cell culture flasks in 5% CO2 at 
37°C.  Floating microglia were harvested between 2-8 weeks, either seeded into 24-well 
plates for primary microglia culture, or re-seeded back into 24-well plates (2x105) for 
other assays.  After 30mins, cultures were washed to remove non-adherent cells and fresh 
medium was added, and the cultures were treated 24h after seeding. 
Immunocytochemistry 
Same as that mentioned in chapter 2, except the following: In the double-labeling of OX-
42 (1:1000) and NF-kB p65 (1:125), the color was developed with nickel-intensified 3,3'-
diaminobenzidine in Tris buffer during the final step.   
PGE2 production 
PGE2 in the supernatant was measured with a PGE2 EIA kit from Cayman (Ann Arbor, 
MI, USA) according to the manufacturer’s instructions.  The supernatant from primary 
microglia-enriched culture (2x105cells/well) was measured for total PGE2 production. 
The culture medium was removed for extracellular PGE2 measurement and 1ml PBS was 
added into each well plate followed by sonication 3 times X 6 seconds for intracellular 
PGE2 measure.  For the PPARγ inhibition study, T0070907 (1nM) was added into culture 
medium 1hr prior to either pioglitazone (10μM) and / or LPS (1μg/ml) treatment for 48hr. 
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Western blot 
Cells were collected and lysed for western blot analysis of COX-2, NF-kB and phospho-
JNK.  Protein concentrations were determined with the bicinchoninic acid assay 
following the manufacturer's guide.  Equal amounts of protein were separated by a SDS 
PAGE gel and were transferred to polyvinylidene difluoride membranes.  Membranes 
were blocked with 5% nonfat milk and incubated with polyclonal anti-COX2 antibody 
(1:1000), polyclonal anti-NF-kB antibody (1:1000), and monoclonal anti-phospho-JNK 
(1:1000) either for 1hr at room temperature or overnight at 4°C.  Peroxidase-linked anti-
rabbit or anti-mouse IgG (1:4000; 1hr at 25°C) and ECL-Plus reagents (Amersham 
Biosciences Inc., Piscataway, NJ) were used as a detection system.  The optical density 
was measured using the scion imageTM software (Frederick, MD, USA). 
Statistical Analysis 
The data are expressed as the mean ± SEM and statistical significance was assessed by 
ANOVA followed by a Tukey comparisons test using the SYSTAT 10 software (SPSS 
Inc., Chicago, Illinois).  A value of p < 0.05 was considered statistically significant.  Data 
presented represent three independent experiments.  
 
Results  
Pioglitazone inhibits LPS-induced COX-2 / PGE2 expression in microglia-enriched 
cultures 
PGE2 generated by COX-2 is a major component of the innate immune response.  
Previous reports have shown that LPS strongly activates microglia, induces COX-2 
expression, and enhances PGE2 synthesis (Bauer et al., 1997; Fiebich et al., 2003).  In 
this set of experiments, LPS-induced COX-2 expression was tested in the presence and 
absence of pioglitazone.  Western blot analysis revealed that COX-2 was undetectable 
under basal conditions and with pioglitazone treatment, but COX-2 expression increased 
with LPS treatment.  The LPS-induced increase was suppressed by pretreatment with 
pioglitazone (10μM) (Figure 3.1).  In addition, a 24hr LPS challenge (1μg/ml and 
10μg/ml) induced a 50 and 100-fold induction of PGE2 (p<0.001), and pioglitazone 
significantly attenuated PGE2 generation (p<0.01, Figure 3.2). 
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Figure 3. 1 Pioglitazone inhibits LPS-induced COX-2 expression. 
Primary mesencephalic cultures (1×106 cells/well) were treated with 1μg/ml LPS for 6 h, 
and LPS treatment upregulated COX-2 expression.  Pretreatment with pioglitazone 
(10μM) reduced COX-2 expression.  
 
 
 
 
 
Figure 3. 2 Pioglitazone inhibits LPS-induced PGE2 synthesis in microglia-enriched 
cultures. 
In rat microglia-enriched cultures (2×105 cells/well), LPS (1μg/ml) increased PGE2 about 
50 fold in 24h, and pretreatment with pioglitazone 1h prior to LPS administration 
significantly decreased PGE2 generation.  The data were expressed as the percentage of 
control and were the mean ± SEM, from three independent experiments. (n=3) (**p<0.01 
versus control; ***p<0.001 versus control; ##p<0.01 versus LPS). 
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Inhibition of COX-2 protects dopaminergic neurons against LPS challenge 
In order to confirm whether inhibition of COX-2 activity protects dopaminergic neurons 
from LPS exposure, a selective COX-2 inhibitor (CAY10404, 1μM) was used in neuron-
microglia mixed culture, 1hr before a 96h LPS exposure.  As shown in Figure 3.3, 
inhibition of COX-2 protects dopaminergic neurons against LPS treatment (p<0.05).  
 
 
 
Figure 3. 3 Inhibition of COX-2 protects dopaminergic neurons against LPS insult in rat 
neuron-microglia mixed cultures. 
Microglia (2×105 cells/well) were added back into neuron-enriched cultures (1×105 
cells/well) at DIV6 along with 1 μM CAY10404 (a specific COX-2 inhibitor) 1 h before 
a 96 h LPS (1μg/ml) treatment.  TH-positive immunostained neurons were counted and 
the results show that COX-2 inhibition protects the neurons.  The data were expressed as 
the percentage of control and were the mean ± SEM, from three independent experiments. 
(n=3) (**p<0.01 versus control; #p<0.05 versus LPS). 
 
 
 
 39
Suppression of PGE2 generation by pioglitazone is associated with interference with NF-
kB and JNK activity  
Since both the JNK and NF-kB pathways are involved in the proinflammatory response 
to LPS insult (Hambleton et al., 1996), we tested whether pioglitazone can suppress JNK 
and NF-kB phosphorylation.  As shown in Figure 3.4, LPS (1μg/ml) increased the 
amount of phosphorylated JNK (Thr-183 and Tyr-185) and phosphorylated NF-kB (p65 
at ser276).  In contrast, pioglitazone treatment, 1hr before LPS, inhibited the 
phosphorylation of JNK and NF-kB (p<0.05).  To investigate our hypothesis that 
pioglitazone inhibits NF-kB nuclear translocation in microglia, immunostaining of OX-
42 (an indicator for microglia) and phosphorylated NF-kB p65 was performed in primary 
mesencephalic culture, and NF-kB nuclear translocation was observed in microglia upon 
LPS (1μg/ml) treatment (Figure 3.5 b).  In contrast, pretreatment with pioglitazone 
suppressed NF-kB nuclear translocation (Figure 3.5 d).  
To further determine if inhibition of JNK or NF-kB leads to the suppression of 
PGE2 generation, sulfasalazine, a selective NF-kB inhibitor, and SP600125, a selective 
JNK inhibitor, were used in microglia-enriched cultures, 1hr before LPS treatment 
(1μg/ml and 10μg/ml).  As shown in Figure 3.6, a 50 and 130-fold increase in PGE2 
generation were found, respectively (p<0.01 or p<0.001).  Pretreatment with 
sulfasalazine (10μg/ml) or SP600125 (5μM) significantly suppressed PGE2 generation 
after a 24h LPS exposure (p<0.01). 
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Figure 3. 4 Pioglitazone inhibits LPS-induced phosphorylation of JNK and NF-kB in 
neuron-microglia mixed cultures. 
A: Microglia were added back into neuron-enriched cultures, and increased 
phosphorylated JNK and NF-κB were found upon 1μg/ml LPS exposure. Pretreatment 
with pioglitazone (10μM), for 1 h, inhibited JNK phosphorylation (Thr-183 and Tyr-185) 
and NF-κB p65 (Ser276) phosphorylation.  B and C: Densitometric measurements 
showed LPS-induced increased JNK (B) and NF-kB (C) phosphorylation and inhibition 
by pioglitazone.  The data were expressed as the percentage of control and were the mean 
± SEM, from three independent experiments. (*p<0.05 versus control; #p<0.05 versus 
LPS). 
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Figure 3. 5 Pioglitazone inhibits NF-kB nuclear translocation in microglia upon LPS 
stimuli. 
Primary mesencephalic cultures (1×105 cells/well) were immunostained with anti-OX-42 
antibody (1:1000), followed by anti-NF-κB p65 (1:125) staining.  In the control group, 
NF-κB p65 staining (dark blue) was in the cytoplasm (a), however, sixty minutes of LPS 
(1μg/ml) exposure induced NF-κB p65 nuclear translocation, as shown by the arrow in 
(b).  Both the pioglitazone group (c) and pioglitazone plus LPS group (d) showed that 
NF-κB p65 staining was in the cytoplasm, rather than the nucleus, suggesting that 
pretreatment with pioglitazone 1 h before LPS treatment suppressed NF-κB nuclear 
translocation.  
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Figure 3. 6 Inhibition of NF-kB and JNK reduces PGE2 generation in microglia-enriched 
cultures. 
Microglia-enriched cultures (2×105 cells/well) were treated 24 h after seeding, and a 24h 
LPS (1μg/ml) treatment induced PGE2 generation in a dose-dependent manner.  The NF-
kB inhibitor (Sulfasalazine) or JNK inhibitor (SP600125) was added 1 h before the LPS 
treatment and the LPS induced PGE2 generation was significantly reduced.  The data 
were expressed as the percentage of control and were the mean ± SEM, from three 
independent experiments. (n=3) (**p<0.01 versus control; ***p<0.001 versus control; 
##p<0.01 versus LPS 1μg/ml). 
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A PPARγ antagonist failed to reverse pioglitazone inhibition of LPS-induced PGE2 
generation in primary microglia-enriched culture  
Our preliminary study suggested that PGE2 generation induced by LPS is PPARγ-
independent.  In order to investigate the possibility that pioglitazone inhibition of LPS-
induced PGE2 might be PPARγ-dependent in terms of intracellular and extracellular 
PGE2, a highly selective antagonist T0070907 was used in the primary microglia-
enriched culture.   Forty-eight hour exposure to LPS (1μg/ml) stimuli induced a ~20 fold 
increase in the extracellular PGE2 level, and pretreatment with pioglitazone significantly 
inhibited it (Figure 3.7 A, p<0.05), however, T0070907 (1nM) failed to show reversing 
effect on the inhibition of LPS-induced PGE2 by pioglitazone. The similar response 
pattern was observed to measure intracellular PGE2 level, and pioglitazone decreased its 
level, however, pretreatment with T0070907 (1nM) did not show its reversing effect on 
the PGE2 inhibition by pioglitazone (Figure 3.7 B). 
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Figure 3. 7 Effect of T0070907 on the pioglitazone inhibition of LPS-induced PGE2 
generation. 
Primary microglia-enriched culture (2x105/well) was treated with T0070907 (1nM) either 
alone or plus pioglitazone (10μM) and / or LPS (1μg/ml) for 48hr, then extracellular and 
intracellular PGE2 levels were measured (Figure 3.7 A and B).  A: (extracellular PGE2) 
Pioglitazone inhibited LPS-induced PGE2 levels, pretreatment with T0070907 did not 
block the inhibition of LPS-induced PGE2 production by pioglitazone. B: (intracellular 
PGE2) a similar pattern was found. Pretreatment with T0070907 (1nM) failed to reverse 
pioglitazone inhibition of LPS-induced PGE2.  The data were expressed as the percentage 
of control and were the mean ± SEM, from three independent experiments. (n=3) 
(**p<0.01 versus control; #p<0.05 versus LPS; ##p<0.01 versus LPS). 
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Discussion 
In the previous chapter, our results showed that pioglitazone protects dopaminergic 
neurons against LPS neurotoxicity via inhibiting microglia activation.   
In this chapter, LPS-induced COX-2 and PGE2 was emphasized, and the potential 
interference of the relevant signaling pathways with pioglitazone was investigated.  In 
addition, the potential inhibition of PGE2 by pioglitazone was explored.  The present in 
vitro study demonstrates that the neuroprotective effects of pioglitazone are associated 
with inhibiting JNK and NF-kB pathways, which inhibits the inflammatory reaction by 
attenuating the expression of COX-2 and PGE2 generation, resulting in the survival of 
dopaminergic neurons.  In addition, it appears that the inhibition of PGE2 synthesis by 
pioglitazone might not be PPARγ-dependent.  
COX-2 has been suggested as a key element in the pathological process of PD.  
COX-2 expression in the ventral midbrain of PD brain samples is increased (Teismann et 
al., 2003b) and  COX-2 inhibition or deficiency protects dopaminergic neurons against 
MPTP and 6-OHDA toxicity (Teismann and Ferger, 2001; Sanchez-Pernaute et al., 2004; 
Vijitruth et al., 2006).  Our LPS in vitro PD model demonstrated that pioglitazone 
inhibits COX-2 expression (Hunter et al., 2007).  The present study reports that 
pioglitazone inhibits LPS-induced COX-2 in the primary mesencephalic-microglia mixed 
culture and PGE2 synthesis in microglia.  Combined with the observation that LPS 
neurotoxicity is microglia-dependent described in chapter 2 and inhibition of COX-2 
rescues the neurons, the results suggest that microglia-derived PGE2 may play an 
important role in the detrimental process of dopaminergic neuronal death, and 
pioglitazone provides beneficial effects via inhibiting its synthesis.  Although the 
underlying mechanisms of cellular PGE2–induced neurotoxicity in human are not known, 
the distribution of PGE2 receptors (EP1, 2, 3, and 4) in rat midbrain and the potential 
PGE2 receptor-mediated neurotoxicity in 6-OHDA in vitro model was investigated 
(Carrasco et al., 2007).  Their studies identified EP1 and EP2 receptors on the 
dopaminergic neurons by immunohistochemistry for TH and PGE2 receptors.  
Interestingly, only activation of EP1 receptor is toxic to dopaminergic neurons, in 
agreement with the similar toxicity induced by PGE2 treatment.  In contrast, selective 
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antagonist for EP1 receptor rescues dopaminergic neurons against 6-OHDA insult in 
primary mesencephalic neuronal cultures.   
Based on the aforementioned reports, pioglitazone protects dopaminergic neurons 
probably via inhibiting LPS-induced PGE2 synthesis.  In addition, pioglitazone might 
also regulate EP1 receptor activity to attenuate PGE2-mediated toxicity.  Indeed, this 
could be possible since a PPARβ agonist increased EP4 mRNA and protein levels in 
human lung carcinoma cell line (Han et al., 2005). 
Further study on the NF-kB and JNK activity in mixed cultures showed that 
pioglitazone suppresses their phosphorylation and NF-kB nuclear translocation induced 
by LPS.  In addition, inhibition of NF-kB and JNK activity decreases PGE2 level, 
suggesting not only NF-kB but also JNK mediate COX-2 activity, which is the first 
report demonstrating LPS-induced COX-2-mediated dopaminergic neuronal death in 
vitro model is associated with increased JNK activity.   
Increased NF-kB immunoreactivity and expression were observed in the midbrain 
of PD patients (Hunot et al., 1997; Mogi et al., 2007).  The current study showed that 
pioglitazone inhibits LPS-induced NF-kB phosphorylation and microglial nuclear 
translocation, in agreement with the study on the pioglitazone neuroprotection in MPTP 
animal model (Dehmer et al., 2004).  The underlying mechanisms of the inhibitory effect 
of NF-kB activity by PPARγ agonists are not clearly known due to the wide spectrum of 
gene transcriptions regulated by both PPARγ and NF-kB.  However, results from 
different cell culture systems suggested that PPARγ agonists including synthetic ligands 
inhibit NF-kB activation via PPARγ-independent mechanisms.  For example, the PPARγ 
agonist 15d-PGJ2 inhibits the LPS-induced degradation of IkBα in RAW264.7 cells 
which only express very low PPARγ (Straus et al., 2000; Castrillo et al., 2001).   
The direct implication that JNK activation may be related to the death of 
dopaminergic neurons came from the observation that the JNK inhibitor CEP-1347 
protected neurons against MPTP toxicity (Saporito et al., 1999).  Further results from an 
experimental PD model provided a link between the activation of JNK activation / COX-
2 expression and survival of dopaminergic neurons.  In their studies, MPTP increased c-
JUN phosphorylation in the midbrain, in contrast, the JNK inhibitor CEP-11004 or JNK 
deficiency suppressed its expression accompanied with a decreased COX-2 expression 
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(Teismann et al., 2003b; Hunot et al., 2004).  In the midbrain slice culture system, 
inhibition of JNK activity protects dopaminergic neurons against LPS/IFNγ insult 
(Shibata et al., 2006).  It was suggested that MPTP activates the JNK signaling cascade, 
and JNK kinase (MKK4) / JNK / c-Jun / caspase-3 sequential activation is involved in 
dopaminergic neuronal death (Xia et al., 2001).  Further study on the interference of JNK 
signaling-mediated neuronal loss by pioglitazone will be informative to understand its 
underlying protective mechanisms.   
It is worth noting that T0070907, a highly selective PPARγ antagonist (Lee et al., 
2002), has generated great interest recently as it is more potent and selective (with its IC50 
1nM for rosiglitazone) than other antagonists such as GW9662.  We used T0070907 to 
test if the inhibition of LPS-induced PGE2 generation by pioglitazone is PPARγ-
dependent.  Under current experimental condition, no significant blocking effect of 
T0070907 on the inhibition of PGE2 by pioglitazone was observed in the measurement of 
both intracellular-PGE2 and excellular-PGE2 levels, suggesting pioglitazone might 
suppress LPS-induced PGE2 in a PPARγ-independent manner.  One study on the PGE2 
synthesis in lung cancer cell line revealed PPARγ-independent mechanisms since the 
PPARγ antagonist GW9662 did not block pioglitazone-mediated inhibition of PGE2 
generation (Hazra et al., 2007).  On the other hand, another study on the TNFα-induced 
PGE2 production in human smooth muscle cell culture demonstrated a PPARγ-dependent 
effect (Ringseis et al., 2006).  Since pioglitazone inhibits PGE2 synthesis partially via 
inhibiting NF-kB, which can be inhibited by PPARγ agonists via receptor-independent 
mechanisms (Straus et al., 2000; Castrillo et al., 2001), the PPARγ-independent inhibition 
of PGE2 in our cell culture system may be related to the PPARγ-independent inhibition of 
NF-kB.  PPARγ knockdown will be very helpful to address if its inhibitive effect on 
PGE2 is receptor-dependent or independent.  
The aforementioned studies indicate that the neuroprotective effects of 
pioglitazone are associated with its blocking multiple proinflammatory signaling 
pathways, including NF-kB and JNK pathways.  However, its potential inhibitory effect 
on microsomol PGE synthase-1 (mPGES-1), which is the enzyme converting PGD2 to 
PGE2, cannot be ruled out, since LPS administration in vivo and in vitro causes persistent 
upregulation of mPGE-1 (Devaux et al., 2001; Ajmone-Cat et al., 2003).  In addition, 
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activation of PPARγ blocked the up-regulation of COX-2, mPGES-1, and PGE2 in mouse 
embryo fibroblasts (Kapoor et al., 2007).  Therefore, in the future, it would be very 
interesting to determine if pioglitazone influences mPGES-1 activity in our cell culture 
systems. 
In summary, the studies described in the current chapter suggest that the 
neuroprotective effects of pioglitazone are associated with the inhibition of JNK and NF-
kB pathways as well as with the suppression of COX-2 activity and decreased PGE2 
generation, probably via PPARγ-independent mechanisms.  This ultimately protects 
dopaminergic neurons via attenuating microglia-mediated and inflammation-induced 
neurodegeneration.   
In the next chapter 4, LPS-induced iNOS / NO and its inhibition by pioglitazone 
via suppression of p38 MAPK signaling pathway will be emphasized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Bin Xing 2008
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CHAPTER 4: Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide 
synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt 
(From published paper: B Xing, T Xin, RL Hunter, GY Bing. (2008) J. Neuroinflammation 5:4). T Xin took 
part in Western blot; RL Hunter took part in experimental design. 
 
Introduction 
Chapter 2 demonstrated that LPS neurotoxicity is microglia-dependent, and pioglitazone 
protects dopaminergic neurons via inhibiting microglia activation.  In chapter 3, the study 
suggested that pioglitazone protects dopaminergic neurons against LPS insult by 
suppressing COX-2 expression and PGE2 synthesis via interfering with NF-kB and JNK 
pathways.  In this chapter, LPS-induced iNOS and NO generation are emphasized, and 
the following questions are discussed: 1) the inhibitory effects of pioglitazone on LPS-
induced iNOS and NO production; 2) the potential differential role of p38 MAPK and 
JNK pathway in the LPS-induced NO generation; 3) the potential differential mediation 
of p38 MAPK and JNK by pioglitazone; 4) the potential mediation of PI3K / Akt activity 
by pioglitazone and its effect on NO generation.   
One of the major effectors responsible for neurodegeneration is NO.  Under 
normal condition, NO is a necessary component for synaptic transmission (Bredt, 1999).  
Under pathological condition, however, excessive NO can react with superoxide and 
form the lipid-permeable oxidant peroxynitrite which can directly oxidize proteins, lipids, 
and DNA.  In addition, peroxynitrite can disrupt mitochondria function (Brown, 1999) 
and is related to mitochondria-driven reactive oxygen and reactive nitrogen species 
production (Poderoso et al., 1996), ultimately resulting in cell death.   
Twenty years ago, postmortem analysis revealed that a great number of activated 
microglia surround dopaminergic neurons in the SN of PD brain samples (McGeer et al., 
1988b).  Recent postmortem studies provided evidence on the detrimental role of 
activated microglia-mediated iNOS / NO in dopaminergic neuron degeneration.  In their 
studies upregulated microglial iNOS expression was observed in the SN of PD brain 
(Hunot et al., 1996; Knott et al., 2000).  The experimental studies demonstrated that 
increased iNOS activation is associated with the death of dopaminergic neurons in vitro 
(Okuno et al., 2005; Lin et al., 2007) and in vivo (Liberatore et al., 1999; Teismann and 
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Ferger, 2001; Arimoto and Bing, 2003).  In contrast, inhibition of iNOS showed 
neuroprotection toward dopaminergic neurons against toxic insults (Wang et al., 2002; 
Katsuki et al., 2006).   
p38 MAPK and JNK pathways are two main signaling cascades modulating 
inflammatory response and stress (Kyriakis and Avruch, 2001).  Experimental in vitro 
study suggested that activation of p38 MAPK is involved in LPS-induced insults in glial 
cells (Bhat et al., 1998).  Activated microglia-induced cortical neuronal death has been 
attributed to p38 MAPK activation (Xie et al., 2004), and inhibition of p38 MAPK 
activity rescued dopaminergic neurons from a thrombin-activated microglia insult (Lee et 
al., 2005).  Recent LPS in vitro and in vivo studies strongly implicated a role of p38 
MAPK in the LPS-induced microglia-mediated dopaminergic neuronal loss.  Inhibition 
of p38 MAPK pathway by its inhibitor protected neurons and NO production in the 
primary mesencephalic culture was decreased (Jeohn et al., 2002).  The other study 
showed that intranigral co-injection of LPS with p38 MAPK inhibitor rescued 
dopaminergic neurons in the SN, accompanied with reduced iNOS expression (Ruano et 
al., 2006).  In contrast, the role of the JNK pathway in the LPS model is less studied.  The 
result from a midbrain slice culture study suggested that inhibition of JNK activity 
rescues LPS/IFNγ-induced dopaminergic neuronal loss without influencing iNOS 
expression (Shibata et al., 2006).  However, in their studies the role of astrocytes was not 
ruled out, and the potential role of JNK pathway in the mediation of LPS-induced NO 
were not tested.   
One study on mouse peritoneal macrophages demonstrated that the PPARγ 
agonist 15d-PGJ2 suppresses IFN-γ-induced iNOS protein and its mRNA (Ricote et al., 
1998).  An in vivo study demonstrated that the PPARγ agonist troglitazone suppresses 
cerebellular iNOS expression and protected cerebellular granule cells against LPS/IFN-γ 
insult (Heneka et al., 2000).  A very recent study on the experimental PD model 
demonstrated that the PPARγ agonist pioglitazone protected dopaminergic neurons from 
MPTP insult, and iNOS-positive microglial cells were suppressed (Breidert et al., 2002); 
further study from the same research group suggested that pioglitazone protected TH 
positive neurons against MPTP insult probably via PPARγ activation and suppression of 
 
 51
iNOS expression (Dehmer et al., 2004).  However, whether the inhibition of iNOS by 
pioglitazone is PPARγ-dependent or PPARγ-independent is still not defined.   
The above studies strongly suggested that PPARγ agonists protect dopaminergic 
neurons via inhibiting microglial iNOS expression.  However, several questions remain 
to be addressed.  First, the role of pioglitazone in mediating LPS-induced NO production 
in microglia has not been studied; Second, the role of pioglitazone in the LPS-induced 
p38 MAPK pathway have not been investigated.  So, the first hypothesis in this chapter is 
that pioglitazone inhibits LPS-induced NO generation probably via interference with p38 
MAPK and JNK pathways.  The first specific aim is to test 1) the inhibitory effect of 
pioglitazone on LPS-induced NO generation (by nitrite assay) in primary microglia 
cultures and iNOS expression (by western blot) in mixed cultures, 2) the inhibitory effect 
of pioglitazone on LPS-induced p38 MAPK in mixed cultures (by western blot), 3) the 
effect of p38 MAPK and JNK inhibition on NO production in microglia by using their 
selective inhibitors, and 4) if the inhibition of LPS-induced NO generation by 
pioglitazone is PPARγ-dependent or PPARγ-independent. 
PI3K / Akt is a well-known cell survival signaling pathway (Brazil and 
Hemmings, 2001).  Neurotrophic factors such as nerve growth factor promote neuronal 
survival via activating the PI3K/Akt cascade (Halvorsen et al., 2002; Nusser et al., 2002; 
Bonnet et al., 2004; Zhou et al., 2004; Yoshii and Constantine-Paton, 2007).  On the 
other hand, PI3K/Akt mediates both the apoptosis and inflammatory responses (Cantley, 
2002).  Inhibition of PI3K by LY294002 promoted MPP+-induced SH-SY5Y apoptosis, 
and activation of Akt can protect cells (King et al., 2001).  Nerve growth factor treatment 
prevented MPP+-induced SH-SY5Y apoptosis possibly via increasing the 
phosphorylation of PI3K / Akt (Halvorsen et al., 2002).  Recent studies demonstrated that 
the PI3K/Akt pathway inhibits the inflammatory response in monocytes via inhibiting the 
JNK and p38 MAPK pathways (Guha and Mackman, 2002).  It is interesting to know if 
PI3K differentially mediates p38 MAPK and JNK activity inhibiting LPS-induced NO.  
Although the potential effects of PPARγ agonists on the PI3K activity have not been 
studied, one study on the LPS-induced iNOS in mucous acinar cells demonstrated that the 
PPARγ agonist ciglitazone inhibited its expression and inhibition of PI3K countered its 
inhibitive effect (Slomiany and Slomiany, 2003).  Whether pioglitazone alters the activity 
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of PI3K/Akt pathway and thus inhibits LPS-induced NO is a very interesting question.  
The second hypothesis is that 1) the PI3K pathway takes part in LPS-induced p38 MAPK 
/ JNK activation; 2) pioglitazone alters activation of the PI3K/Akt pathway.  The second 
aim is to test 1) if inhibition of PI3K activity increases LPS-induced p38 MAPK and JNK 
phosphorylation (western blot), by using the PI3K selective inhibitor wortmannin; 2) if 
inhibition of PI3K increases LPS-induced p38 MAPK-mediated NO production in 
primary microglia culture (nitrite assay); and 3) if PI3K / Akt activity is altered by 
pioglitazone treatment (western blot). 
 
Methods 
Animals 
Thirty two timed-pregnant Sprague Dawley rats were obtained from Harlan (Indianapolis, 
IN, USA), and maintained in a pathogen-free environment.  Housing, breeding, and 
experimental use of the animals were performed in strict accordance with the National 
Institutes of Heath guidelines and were approved by the Institute’s Animal Care and Use 
Committee at the University of Kentucky. 
Reagents 
Same as these mentioned in chapter 2 and 3 except the following:  T0070907-PPARγ 
antagonist and 1400W-iNOS inhibitor from Cayman Chemical (Ann Arbor, MI, USA), 
SP600125-JNK inhibitor and SB203580-p38 inhibitor from A.G. Scientific (San Diego, 
CA, USA), and wortmannin-PI3K inhibitor from Sigma-Aldrich.  Antibodies: polyclonal 
anti-iNOS from Millipore (Billerica, MA, USA), monoclonal anti- phospho p38 from 
Cell Signaling (Danvers, MA, USA), monoclonal anti-PPARγ (ser473) from Upstate 
(Billerica, MA, USA), polyclonal anti-PI3K p110 and polyclonal anti-Akt (Thr308) from 
Santa Cruz (Santa Cruz, CA, USA). 
Mesencephalic neuron-microglia mixed cultures 
Same as that mentioned in chapters 2 and 3. 
Primary mesencephalic neuron-enriched cultures 
Same as that mentioned in chapters 2 and 3. 
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Microglia-enriched cultures 
Same as that mentioned in chapters 2 and 3. 
Nitrite oxide assay 
The production of NO was assessed by the accumulation of nitrite in culture supernatants 
by using the colorimetric reaction of the Griess reagent.  Culture supernatants were 
collected at different time points following LPS stimulation and were mixed with Griess 
reagent (0.1% N-[1-naphthyl] ethylenediamine dihydrochloride, 1% sulfanilamide, and 
2.5% H3PO4).  The absorbance at 548nm was measured with a spectraMAX microplate 
reader from Molecular Devices (Sunnyvale, CA, USA).  For the PPARγ inhibition study, 
T0070907 (1nM) was added into the culture medium 1hr prior to either pioglitazone 
(10μM) and / or LPS (1μg/ml) treatment for 48hr. 
Western blot 
Same as that described in chapters 2 and 3 except different antibodies were used.  The 
antibodies and their concentrations used in western blot are: Polyclonal anti-iNOS 
antibody (1:1000), monoclonal anti-p38 (1:2000), monoclonal anti-PPARγ (1:250), 
polyclonal anti-PI3K p110 (1:250), and polyclonal anti-Akt (1:250). 
Statistical analysis 
The data are expressed as the mean ± SEM and statistical significance was assessed by 
ANOVA followed by a Tukey comparisons test using the SYSTAT 10 software (SPSS 
Inc., Chicago, Illinois).  A value of p<0.05 was considered statistically significant.  
 
Results  
Pioglitazone inhibits LPS-induced nitric oxide generation in microglia-enriched cultures 
To determine the effect of the PPARγ agonist pioglitazone on NO generation, two 
different doses of pioglitazone (1μM and 10μM) were administered to microglia-enriched 
cultures 1hr before LPS (1μg/ml) treatment.  LPS induced a 4-fold increase in NO 
generation (p<0.001) after 48hr, and pretreatment with pioglitazone reduced NO 
production by about 40% to 60% (p<0.001), respectively (Figure 4.1).  However, 
administration of pioglitazone concurrent with LPS, or 1hr after LPS, failed to inhibit the 
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LPS-induced NO increase (Figure 4.2).  In addition, pioglitazone alone did not alter NO 
production. 
 
 
 
 
Figure 4. 1 Pioglitazone inhibits LPS-induced NO production in microglia-enriched 
cultures. 
Microglia cultures (2x105 cells/well) were treated with pioglitazone (1 μM and 10μM) 1 
hr before LPS treatment, and 48 h later NO levels were measured. LPS significantly 
induced NO generation, and pretreatment with pioglitazone inhibited this LPS-induced 
NO production in a dose-dependent manner.  The data were expressed as the percentage 
of control and were the mean ± SEM, from three independent experiments. (n=3) (***p < 
0.001 versus. control;  ###p < 0.001 versus. LPS) 
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Figure 4. 2 Post-treatment of pioglitazone did not show inhibition of LPS-induced NO 
production in microglia-enriched cultures 
Pioglitazone was added with LPS at the same time or 1 hr after LPS treatment in 
microglia-enriched cultures (2x105 cells/well), and 48 h later NO levels were measured.  
A: pioglitazone was added with LPS at the same time. B: pioglitazone was added 1h after 
LPS treatment.  In both A and B, LPS significantly induced NO generation, however, no 
inhibitory effect of NO was observed.  The data were expressed as the percentage of 
control and were the mean ± SEM, from three independent experiments. (n=3) (***p < 
0.001 versus. control) 
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Pioglitazone inhibits LPS-induced iNOS expression, and iNOS inhibition protects 
dopaminergic neurons from LPS insults in mesencephalic mixed cultures 
In this set of experiments, iNOS expression was determined by western blot performed 
48h after LPS (1μg/ml) treatment.  As shown in Figure 4.3, basal iNOS expression was 
decreased by pioglitazone (p<0.001), LPS treatment produced significantly enhanced 
iNOS expression (p<0.01), and pretreatment with pioglitazone (10μM) significantly 
reduced this LPS-induced increase in iNOS expression (p<0.01).  In addition, we used 
immunocytochemistry for TH-positive cells to assess the effect of a specific iNOS 
inhibitor, 1400W (1nM to 10μM), on the survival of dopaminergic neurons 72hr after 
LPS treatment.  Figure 4.4 shows that LPS induces a significant loss (90%) of the TH-
positive neurons when the iNOS inhibitor is administered 1hr before LPS (1μg/ml).  
Partial neuroprotection against the LPS insult was seen when using 1400W at 100nM 
(p<0.05) and 1μM (p<0.001).  
 
 
 
Figure 4. 3 Pioglitazone inhibits LPS-induced iNOS expression. 
Rat mesencephalic mixed cultures (2x106cells/well) were treated with 1 μg/ml LPS for 48 
hours.  LPS treatment upregulated the expression of iNOS, and pretreatment with 
pioglitazone (10 μM), 1 hr before LPS, prevents its expression.  The data were expressed 
as the percentage of control and were the mean ± SEM, from three independent 
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experiments. (n=3) (**p < 0.01 versus. control, ***p < 0.001 versus. control, ##p < 0.01 
versus. LPS). 
 
 
Figure 4. 4 iNOS inhibition protects dopaminergic neurons from LPS insults. 
Rat mesencephalic mixed cultures (2x105 microglia added) were treated with the 
selective iNOS inhibitor 1400 W, with different doses from 1 nM to 1μM, 1 hr before a 
72 hr LPS exposure.  The number of TH-positive neurons was determined by 
immunocytochemistry.  The data were expressed as the percentage of control and were 
the mean ± SEM, from three independent experiments. (n=3) (***p < 0.001 versus. 
control, #p < 0.05 versus. LPS, ###p < 0.001 versus. LPS). 
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Pioglitazone reduces NO levels by inhibition of p38 MAPK activity 
In this set of experiments, pretreatment with pioglitazone (10μM) 1hr before LPS 
(1μg/ml) decreased phosphorylation of p38 MAPK (Figure 4.5), and pretreatment with 
wortmannin (1μM and 10μM) increased LPS-induced p38 MAPK phosphorylation in a 
dose-dependent manner (Figure 4.6 A-C. p<0.05).  An increase in phosphorylation of 
p38 MAPK was not found when wortmannin was administered alone, without LPS 
stimuli (Figure 4.6 D).  Wortmannin also did not change JNK expression (Figure 4.6 A 
and C).  In addition, two proinflammatory pathways were examined, in order to 
demonstrate their involvement in the LPS-induced increase in NO production.  Either 
SB203580 (a selective p38 MAPK inhibitor) or SP600125 (a selective JNK inhibitor) 
was administered to microglia-enriched cultures 1hr before LPS (1μg/ml) exposure.  As 
shown in Figure 4.7, LPS significantly increased NO generation (p<0.001) and inhibition 
of p38 MAPK activity by pretreatment with SB203580 (5μM) decreased this NO 
production (p<0.05).   
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Figure 4. 5 Pioglitazone inhibits LPS-induced p38 MAPK activity. 
Pretreatment with pioglitazone inhibited LPS-induced phosphorylation of p38 MAPK in 
mesencephalic neuronal-microglia mixed cultures.  Pioglitazone was added 1 hr before 
LPS treatment (1 μg/ml) and p38 MAPK was immunobloted.  LPS increased 
phosphorylation of p38 MAPK, and pretreatment with pioglitazone inhibited this 
expression.  The data were expressed as the percentage of control and were the mean ± 
SEM, from three independent experiments. (*p < 0.05 versus. control, #p < 0.05 versus. 
LPS). 
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Figure 4. 6 Inhibition of PI3K activity increases LPS-induced p38 MAPK activity upon 
LPS stimuli. 
Wortmannin (1 μM and 10 μM) was administered to mesencephalic neuron-microglia 
mixed cultures alone or before LPS (1 μg/ml) was added and, after 30 mins, p-JNK and / 
or p-p38 MAPK was immunobloted.  A: In the absence of LPS stimuli, inhibition of 
PI3K did not increase p38 MAPK phosphorylation.  B: Upon LPS stimuli, inhibition of 
PI3K increases p38 MAPK phosphorylation rather than JNK phosphorylation. C: 
Densitometric measurements showed that in the presence of LPS stimuli, inhibition of 
PI3K increased p38 MAPK phosphorylation. D:  Densitometric measurements showed 
that in the presence of LPS stimuli, inhibition of PI3K did not increase JNK 
phosphorylation.  The data were expressed as the percentage of control and were the 
mean ± SEM, from three independent experiments. (*p < 0.05 versus. wortmannin 1μM 
plus LPS). 
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Figure 4. 7  Inhibition of p38 MAPK decreases LPS-induced NO generation in microglia-
enriched cultures. 
A selective p38 MAPK inhibitor (SB203580), or a selective JNK inhibitor (SP600125), 
was added to microglia-enriched cultures 1 hr before LPS (1 μg/ml) exposure and, after 
24 h, NO levels were measured.  The inhibition of LPS-induced NO was only found 
using SB203580.  The data were expressed as the percentage of control and were the 
mean ± SEM, from three independent experiments. (n=3) (***p<0.001 versus control; 
#p<0.05 versus LPS) 
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The alteration of PPARγ activity is not shown in primary neuron-enriched cultures upon 
pioglitazone treatment and LPS insult  
As shown in Figure 4.8, in primary neuron-enriched culture, activation of PPARγ by 
pioglitazone is not observed.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 8  Activation of PPARγ by pioglitazone is not observed in the primary neuron-
enriched culture. 
Primary neuron-enriched cultures (2 × 106 cells/well) were treated with pioglitazone (10 
μM) 1 hr before LPS (1 μg/ml) exposure.  PPARγ activation was assessed after 10 min.  
PPARγ activation was not observed in the both pioglitazone- and LPS-treated group.  The 
data were from three independent experiments. (c=control, L1=LPS (1 μg/ml), P10 
=pioglitazone (10 μM)).  
 
Inhibition of PI3K activity prevents the inhibitory effect of pioglitazone on LPS-induced 
NO production and pharmacological inhibition of PPARγ activity increases LPS-induced 
NO level  
To determine if pioglitazone enhances PI3K/Akt expression and if its inhibition enhances 
LPS-induced NO generation, the levels of PI3K and Akt were determined.  PPARγ, PI3K, 
and Akt phosphorylation were measured after LPS (1μg/ml) exposure.  As shown in 
Figure 4.9, PPARγ activation was observed in pioglitazone-treated cultures within 10min 
after DMSO or LPS.  PI3K and phosphorylated Akt were increased 60min after LPS in 
the pioglitazone-treated cultures (p<0.05).  Next, wortmannin (1μM) was added 30mins 
before pioglitazone (10μM) treatment and the NO level was measured 48h after LPS 
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(1μg/ml).  The results showed that pretreatment with pioglitazone inhibited the LPS-
induced NO increase (Figure 4.10, p<0.01).  However, when wortmannin was given 
30mins before pioglitazone, NO production was increased over LPS exposure (p<0.05).  
Interestingly, administration of wortmannin (1μM) 30min before pioglitazone followed 
by LPS 1hr later did not show the inhibitive effect of pioglitazone on NO level.   
Wortmannin alone, or together with pioglitazone, did not influence NO generation 
without LPS stimulation.  Thus, pioglitazone prevents LPS-induced NO production, and 
pretreatment with wortmannin increases NO generation (Figure 4.10).  As shown in 
Figure 4.11, pretreatment with T0070907 (1nM) reverses the inhibitive effect of 
pioglitazone on the LPS-induced NO production (p<0.001). 
 
 
 
Figure 4. 9 Pioglitazone activates PPARγ and enhances PI3K/Akt activity. 
Rat mesencephalic cultures (2 × 106 cells/well) were treated with pioglitazone (10 μM) 
only, or 1 hr before LPS (1 μg/ml) exposure.  A: PPARγ activation was assessed after 10 
min, and P13K and Akt were assessed after 60 min.  PPARγ activation, PI3K and Akt 
expression were observed in the pioglitazone-treated cultures, compared to control and 
LPS alone groups.  B: Densitometric measurements showed that the expression of 
phosphorylated PPARγ, PI3K, and Akt is higher than control group and LPS alone group.  
The data were expressed as the percentage of control and were the mean ± SEM, from 
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three independent experiments. (*p < 0.05 versus. control, #p < 0.05 versus. LPS, ##p < 
0.01 versus. LPS). 
 
 
 
 
Figure 4. 10 PI3K negatively regulates the LPS-induced increase in NO production. 
The specific PI3K inhibitor wortmannin (1 μM) was administered individually 90 mins 
before LPS treatment (1 μg/ml), or 30 mins before pioglitazone followed by LPS 60 mins 
later in microglia-enriched culture, and after 48 h NO levels were measured. The results 
show that the LPS-induced NO level was significantly higher than control (p < 0.01), and 
that pretreatment with pioglitazone inhibits LPS-induced NO (p < 0.01).  In contrast, 
pretreatment with wortmannin enhanced the LPS-induced increase in NO generation (p < 
0.05), and this pretreatment reversed the inhibitory effect of pioglitazone on LPS-induced 
NO generation. The data were expressed as the percentage of control and were the mean 
± SEM, from three independent experiments. (n=3) (**p < 0.01 versus. control, #p < 0.05 
versus. LPS, ##p < 0.01 versus. LPS, &&p < 0.01 versus. Piog plus LPS). 
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Figure 4. 11 Effect of PPARγ antagonist T0070907 on the LPS-induced NO production. 
Primary microglia-enriched culture (2x105/well) was treated with T0070907 (1nM) either 
alone or before pioglitazone treatment (10μM), followed by LPS administration (1μg/ml).  
After 48hr, NO production was measured. Pretreatment with T0070907 significantly 
reverses the inhibitive effect of pioglitazone on the LPS-induced NO production.  The 
data were expressed as the percentage of control and were the mean ± SEM, from three 
independent experiments. (n=3) (***p<0.001 vs. control; ###p<0.001 vs. LPS; 
&&&p<0.001 vs. corresponding pioglitazone plus LPS group). 
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Discussion 
In chapter 3, the results suggested that pioglitazone protects dopaminergic neurons by 
inhibiting LPS-induced COX-2 expression and PGE2 synthesis via interference with NF-
kB and JNK pathways.  In this chapter, the results demonstrate that 1) pioglitazone 
protects dopaminergic neurons also via inhibiting LPS-induced iNOS and NO generation, 
2) pioglitazone inhibits NO generation via inhibiting p38 MAPK activity, 3) the 
inhibition of p38 MAPK pathway by pioglitazone might be via the activation of PPARγ 
and PI3K pathway. 
Pretreatment with microglia-enriched cultures with pioglitazone significantly 
inhibited the LPS-induced increase in NO production.  Previous studies have shown that 
pretreatment with pioglitazone decreased iNOS-positive cells in the SN and striatum of 
MPTP-treated mice (Dehmer et al., 2004) as well as decreased iNOS expression in the 
intrastriatal LPS model (Hunter et al., 2007).  These findings support our present results.  
In addition, we failed to observe any inhibitory effect of pioglitazone on LPS-induced 
NO production when pioglitazone was administered concurrent with LPS or 1hr after 
LPS treatment, which suggests that PPARγ-mediated anti-inflammatory pathways and 
LPS-mediated inflammatory pathways might target and interact with common active 
molecules.  There are several potential candidates that can be competitively targeted 
within these two pathways.  The first candidate is LPS-induced MAPK activation.  As 
Camp’s study demonstrated using 293T cells, PPARγ can be phosphorylated by p38 
MAPK at its ser82 residue, and an increase in PPARγ phosphorylation may reduce its 
sensitivity to PPARγ ligands such as pioglitazone (Camp and Tafuri, 1997; Camp et al., 
1999).  The second candidate is CD14, where LPS-induced microglia activation is 
mediated by CD14.  However, the PPARγ agonist 15d-PGJ2 and rosiglitazone negatively 
regulate CD14 mRNA transcription in primary mouse microglia cultures (Xu and Drew, 
2007); although, a caveat to this finding is that 15d-PGJ2 was recently shown not to be a 
biologically relevant PPARγ agonist (Giri et al., 2004).  A third candidate for competitive 
targeting by LPS and PPARγ is RXR.  Recent studies have shown that rosiglitazone 
inhibits LPS-mediated RXR nuclear export, resulting in increased nuclear binding of 
RXR in hepatocytes of mice (Park et al., 2004), and that the RXR agonist, 9-cis retinoic 
acid, inhibits NO production by LPS-activated microglia (Xu et al., 2005).  Our results 
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also demonstrate that inhibition of iNOS, with its specific inhibitor 1400W, protects 
dopaminergic neurons against LPS-induced neurotoxicity.  This data is supported by a 
previous study using an iNOS inhibitor to attenuate dopaminergic neuron loss after 
intranigral LPS treatment (Arimoto and Bing, 2003).  Therefore, we speculate that 
pioglitazone protects dopaminergic neurons at least via inhibition of iNOS expression 
and function, which is consistent with other studies (Dehmer et al., 2004; Hunter et al., 
2007).  
To further clarify which proinflammatory pathways might be involved in 
mediating the inhibition of LPS-induced NO by pioglitazone, selective inhibitors for p38 
MAPK (SB203580) and for JNK (SP600125) were administered before LPS stimulation.  
It is interesting that inhibition of LPS-induced NO production was only observed with 
administration of the p38 MAPK inhibitor, but not with the JNK inhibitor, in microglia-
enriched cultures.  These results suggest that p38 MAPK might be associated with LPS-
mediated iNOS regulation, but not with JNK.  In addition, our study showed that 
pretreatment with pioglitazone before LPS reduces phosphorylation of p38 MAPK, 
which suggests that pioglitazone inhibits LPS-induced iNOS and NO production via 
suppression of p38 MAPK phosphorylation.  Evidence has shown that inhibition of 
different MAPK pathways is associated with decreases in LPS-induced NO production 
(Bhat et al., 1998), where the inhibitory effect of p38 MAPK has been consistently 
observed (Chen and Wang, 1999).  In addition, our results are also consistent with two 
recent in vivo studies which suggest a role for p38 MAPK, but not JNK, in LPS-induced 
activation of iNOS (Ruano et al., 2006; Shibata et al., 2006).  
Inhibition of PI3K with wortmannin did not enhance JNK phosphorylation upon 
LPS stimulation.  In contrast, wortmannin enhanced p38 MAPK phosphorylation upon 
LPS stimulation in a dose-dependent manner, suggesting that PI3K/Akt mediated LPS-
induced p38 MAPK activity and pioglitazone might inhibit LPS-induced NO generation 
via regulation of PI3K/Akt activity. 
Western blot analysis demonstrated that pioglitazone increases PPARγ activation 
followed by PI3K/Akt activation, and LPS treatment has no significant influence on their 
activation.  On the other hand, PPARγ activation by western blot analysis was not found 
in the primary neuron-enriched culture.  The result suggested that the increased PI3K/Akt 
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activity is mainly from microglia.  Generally, these results suggest that activation of the 
PI3K/Akt pathway by pioglitazone might be via PPARγ activation.  Whether the 
activation of PI3K/Akt by pioglitazone is PPARγ dependent or independent needs to be 
further clarified. 
Our present study shows that inhibition of PI3K activity significantly enhances 
LPS-induced NO production.  Furthermore, pretreatment with wortmannin reverses the 
inhibitory effect of pioglitazone on the LPS-induced increase in NO production, 
suggesting that inhibition of NO by pioglitazone may be PI3K-dependent.  Indeed, it 
showed that inhibition of the P13K pathway enhances LPS-induced NO production in 
macrophages (Park et al., 1997).  A more recent study demonstrated that human iNOS 
promoter induction by LPS/IFN-γ is suppressed by PI3K/Akt via inhibition of forkhead 
transcription factor FKHRL1 (Kristof et al., 2006).     
In the current study, it suggests that pioglitazone inhibits LPS-induced NO 
synthesis via PPARγ-dependent mechanisms.  The present results are supported by a 
recent study on the mechanisms of iNOS inhibition by PPARγ agonist Rosiglitazone.  
Their results demonstrated that ligand-binding causes SUMOylation on PPARγ, leading 
to inhibiting the removal of corepressor complex by 19s proteasome on the iNOS 
promoter, thus keeping iNOS transcription in an inactivated status (Pascual et al., 2005).  
The current study shows that pioglitazone significantly inhibits LPS-induced 
microglia-mediated iNOS expression and NO production.  This might be mediated by 
activation of the PI3K/Akt pathway, followed by inhibition of p38 MAPK activity, which 
may contribute to the inhibitory effects of pioglitazone on LPS-induced NO generation; 
thus, protecting dopaminergic neurons against LPS toxicity.  
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CHAPTER 5: Discussion and Conclusions 
Summary of activated microglia-mediated neurodegeneration and its interference 
with PPARγ activation 
Microglia-dependent LPS neurotoxicity to dopaminergic neurons 
The survival study of the dopaminergic neurons upon LPS insult in our culture system 
showed that LPS-induced inflammation-mediated neurotoxicity is microglia-dependent.  
The loss of dopaminergic neurons is only observed in the presence of microglia.  Since 
the finding that reactive microglia surround dopaminergic neurons in the SNpc of PD 
patients (McGeer et al., 1988b), an increasing body of evidence suggested unlimited 
microglial activation upon a variety of stresses may play a major role in the pathogenesis 
of PD.  Although the role of activated microglia as an initial event leading to 
dopaminergic neuronal death has still been under debate, however, the highest density of 
microglia found in the SN of the brain provides the physical base of initial 
neuroinflammatory response.  The in vitro model has advantage over in vivo animal 
model since the molecular mechanisms of activated microglia-mediated dopaminergic 
neuronal death can be investigated more easily via dissecting “initial” pathological events 
in microglia and “secondary” signaling transduction cascades occurring in the 
dopaminergic neurons.  On the other hand, it would be very helpful to identify microglia 
subgroups with different phenotypic and physiological properties.  In this way, the 
microglia subgroups which are more vulnerable to the stress signals and are mainly 
responsible for the release of proinflammatory molecules can be selected out.  It will 
provide valuable tool to develop effective therapeutic strategy for Parkinson’s disease 
and other neurodegenerative diseases.  The number of microglia decreased in the 
pioglitazone plus LPS group.  The cell counting in current study still can not tell whether 
it is due to microglia apoptosis or necrosis. The TUNEL analysis could provide more 
information.   
PPARγ agonist pioglitazone protects dopaminergic neurons against activated microglia-
mediated NO and PGE2 via mediating MAPKs (p38 and JNK) and PI3K activity 
 
PGE2 and NO released from activated microglia are shown to be neurotoxic to 
dopaminergic neurons in primary neuron-microglia cultures.  Pharmacological inhibition 
of JNK and p38 pathways suggests that PGE2 and NO generation induced by LPS might 
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be differentially mediated by JNK and p38 pathways respectively, consistent with other 
studies (Pyo et al., 1998; Han et al., 2002).  The different report from another study 
(Wang et al., 2004) might be due to different cell types in which BV-2 microglia was 
used.  Interestingly, no change of p38 MAPK phosphorylation was observed with the 
inhibition of PI3K by wortmannin in the absence of LPS stimuli.  In contrast, western 
blot analysis showed that inhibition of PI3K activity before LPS insult significantly 
increases the phosphorylation of p38 other than JNK, suggesting PI3K negatively 
mediate LPS-induced p38 activity.  The results from the NO assay also support this 
finding, showing PI3K inhibition in the primary microglia-enriched culture reverses the 
inhibitive effect of pioglitazone on the LPS-induced NO generation, strongly suggesting 
PPARγ agonist pioglitazone suppresses induced-NO in a PI3K-dependent manner.  This 
first report is further supported by the observation in western blotting analysis, showing 
that pioglitazone increases the phosphorylation of PPARγ, followed by PI3K / Akt 
activation in both pioglitazone treated group and LPS treated group.  Due to that 
pioglitazone is administered before LPS treatment, and pioglitazone alone increase 
PI3K/Akt activity, its increases seen in LPS group are more likely originated from 
pioglitazone-induced PPARγ activation.  Since no change of PPARγ activation was found 
in primary neuron-enriched culture upon pioglitazone and LPS treatment, it is more likely 
that the neuroprotective effect of pioglitazone is originated from its dynamic influence on 
the microglia but not on the dopaminergic neurons, which is supported by the evidence 
that PPARγ has only low expression in normal neurons and in the SN even upon MPTP 
insult (Dehmer et al., 2004; Cimini et al., 2005).  Interestingly, a pharmacological PPARγ 
inhibition study using T0070907 suggested that pioglitazone inhibits LPS-induced NO 
production in a PPARγ-dependent, however, inhibition of LPS-induced PGE2． synthesis 
by pioglitazone appears PPARγ-independent.  It is interesting to know whether LPS-
induced PGE2 and NO can in turn influence the phosphorylation of PPARγ in a 
differential way.  
 In summary, pioglitazone protects dopaminergic neurons by inhibiting iNOS and 
COX-2 expression via interference with p38 MAPK and JNK / NF-kB in a differential 
mediating manner, either in a PPARγ-dependent or PPARγ-independent way.  
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Furthermore, the inhibition of iNOS / NO may be mediated by the activation of PPARγ 
and PI3K / Akt pathway. 
 
Potential areas for the further inquiry 
To investigate more effectively whether PPARγ agonist inhibition of LPS-induced NO 
and PGE2 synthesis follows PPARγ-dependent mechanisms, knockdown of PPARγ in the 
primary microglia-enriched cultures could answer this question directly.  The other 
question which is interesting to know is the potential feedback influence of PGE2 and NO 
on the PPARγ activity either in microglia-enriched culture or in primary neuron-enriched 
cultures. Another question that was not directly addressed is the detailed signal 
transduction pathways related to LPS-induced inflammation and oxidative stress in the 
dopaminergic neurons, this could be explored via using conditioned medium from 
activated microglia culture.   
 
Extrapolation to Parkinson’s disease 
From the extracellular signals to intracellular signaling transduction for either cellular 
survival or death, numerous activated molecules take part in this very complicated 
process.  MAPKs and PI3K are the candidates to be preferred targeted and modified since 
1) their signaling cascades are well understood; 2) they are associated with the death or 
survival signaling.  PPARγ agonists have a broad spectrum of biological functions, from 
lipid metabolism in the peripheral tissue to the anti-inflammatory and antioxidant 
properties in the central nervous system, providing a very wide range that can be utilized 
to design effective and selective therapeutic strategies.  By dissecting the molecular role 
of PPARγ activation in the neuroinflammation-mediated MAPKs and PI3K pathways, the 
downstream executive molecules can be identified.  In this way, the undesirable and side 
effects of PPARγ activation on the survival of dopaminergic neurons can be removed by 
specific pharmacological inhibition or gene modification.  For example, what is the 
consequence of long-term treatment of PPARγ agonists in Parkinson’s disease? What is 
the long-term effect of PPARγ agonists on the astrocytes and microglia?  The concern is 
not unnecessary since one study on the human astrocytic cells implicated its apoptotic 
property on these cells  (Chattopadhyay et al., 2000).  The current study suggested that 
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MAPKs pathways have differential function on the mediation of LPS-induced NO and 
PGE2 level, and PPARγ activation inhibits their synthesis probably via PI3K activation 
and accordingly potential differential regulation of MAPKs activity.  The further study on 
the physiological function of PPARγ and their roles in the proinflammatory process may 
be very useful to investigate the possibility of clinical therapy, and further understanding 
the molecular mechanisms of PPARγ agonists on their anti-inflammatory features in 
terms of receptor-dependent or receptor-independent will be very helpful to develop 
PPARγ synthetic drugs with efficacy and safety.  
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